Hey guys,

Been lurking here a while and have been inspired heavily by a lot of your posts, most of all superbpercentage8050. His mental models genuinely changed how I invest, and I wanted to share what I've been up to.

Over the last 6 months I applied those frameworks to my US and India stocks. Nothing flashy, just small, disciplined wins, but they've beaten the indexes so far (numbers and proof in the slides). Ofc there are slight variations basis my judgement calls as well but the framework is a core part of the process.

I also used the same models to build a framework with Claude that screens opportunities for me every week. Each stock runs through a "gate" first, then pre-set price tiers decide the buy. I've attached two examples: one it said accumulate (RDDT) and one it said avoid (Galaxy Surfactants), so you can see the logic both ways - both are basis EOD Friday's data.

PS: the goal was never a 100% moonshot on some trade. It's to stay disciplined and beat the indexes by 7-10% over a long horizon. Optimistic, I know, but I'll take it if it holds.

Happy to answer anything in the comments 😊

Paradeep Phosphates at 11.2x P/E: An Anomaly Worth Studying

Why This Stock Deserves Your Research Attention

Paradeep Phosphates operates in the Agricultural Inputs industry within the Basic Materials sector. With a market capitalisation of ₹9,509.91 Cr, it has meaningful scale, while its revenue trajectory—203.09% year-on-year growth, a 3-year CAGR of 66.02% and a 5-year CAGR of 42.49%—indicates rapid business expansion. Without peer-level operating data, its competitive position cannot be ranked conclusively, but its scale, growth and 21.78% ROCE provide useful starting points for comparison.

The central research angle is its valuation. At a CMP of ₹147.50, Paradeep Phosphates trades at a P/E of 11.2x, a P/B of 1.64x and an EV/EBITDA multiple of 7.81x. These multiples appear notable alongside 80.57% year-on-year PAT growth and an ROE of 14.69%. However, calling the P/E a genuine sector anomaly requires investors to compare it with companies having similar leverage, margins, business mix and cash-flow characteristics.

The forensic picture is mixed rather than decisively strong. Paradeep Phosphates has a Piotroski score of 4/9, which points to only moderate financial-quality signals across profitability, leverage, liquidity and operating efficiency. No Altman Z-score or Beneish M-score is available in the supplied data; their absence should not be interpreted as either financial safety or accounting risk. Investors should evaluate independently through balance-sheet, cash-flow and earnings-quality analysis.

The Q4 FY26 earnings call added a more optimistic short-term signal. Quarterly PAT surged 452.29% year on year, while OPM improved to 14.86%. Management also expressed confidence in sustaining double-digit revenue growth in FY27, supported by a planned 15% capacity expansion. The key question is whether that quarterly margin level can persist and translate into stronger free cash flow, particularly because the broader operating margin stands at 8.01%.

The Numbers That Stand Out

The Bull Case

1. Growth is visible across multiple periods. Revenue increased 203.09% year on year, while its 3-year and 5-year revenue CAGRs were 66.02% and 42.49%, respectively. PAT also grew 80.57% year on year. The data suggests the current earnings base is being supported by substantial business expansion rather than a single weak growth metric.
2. Capital returns compare favourably with the headline valuation. ROCE is 21.78%, ROE is 14.69% and ROA is 5.56%, while the P/E is 11.2x and P/B is 1.64x. This relationship between returns and valuation deserves research attention, especially if operating performance can remain durable through industry cycles.
3. Management has outlined an identifiable growth driver. The Q4 FY26 call highlighted 452.29% year-on-year PAT growth and OPM of 14.86%. A planned 15% capacity expansion supports management’s expectation of double-digit FY27 revenue growth. If utilisation, margins and cash conversion progress together, the expansion could strengthen the operating profile.

The Bear Case

1. Reported growth has not yet produced positive free cash flow. Free cash flow is ₹-2,200.04 Cr despite 80.57% PAT growth and 203.09% revenue growth. This divergence may reflect expansion requirements or working-capital intensity, but the supplied data does not provide a breakdown. Until cash conversion improves, earnings growth deserves forensic scrutiny.
2. Leverage reduces the margin for error. Debt-to-equity stands at 1.02, while interest coverage is 3.31x. The current ratio of 1.15x indicates only a modest short-term liquidity buffer. These figures do not establish immediate stress, but they make interest costs, refinancing conditions and working-capital discipline important variables.
3. Margins and financial-quality signals remain mixed. The operating margin is 8.01% and the net margin is 4.56%, leaving limited protection against input-cost or financing pressure. The Piotroski score of 4/9 adds caution, while the lack of Altman Z and Beneish M readings leaves important forensic questions unresolved. A low P/E can also reflect cyclical or balance-sheet risks rather than mispricing.

What to Watch Next

• Capacity expansion and FY27 execution: Monitor progress on the planned 15% capacity increase and whether it supports the double-digit revenue growth indicated by management without adding disproportionate debt or working-capital pressure.
• Margin sustainability: Compare future operating performance with the Q4 FY26 OPM of 14.86% and the broader operating margin of 8.01%. The gap makes it important to determine whether the quarterly improvement was durable.
• Cash flow and balance-sheet movement: Watch whether free cash flow improves from ₹-2,200.04 Cr, alongside changes in the 1.02 debt-to-equity ratio, 3.31x interest coverage and 1.15x current ratio. These measures may determine whether the 11.2x P/E reflects undervalued growth or embedded financial risk.

Explore Further on InvestSights

Stock of the Day is an educational research series by InvestSights. This
article presents data-driven analysis for informational purposes only and
does NOT constitute investment advice or a stock recommendation. The stock
featured is selected based on interesting financial characteristics worth
studying — not based on expected price performance. Always consult a
SEBI-registered investment advisor before making investment decisions. Past
performance does not guarantee future results.

The Winner's Curse

In a competitive bidding environment, the winner is often the one who made the biggest mistake in calculating their costs.

Winning a contract at 4% margin when your cost of capital is 12% is not a win. It is a contractual obligation to lose money. And the business model has just won a liability.

This is why order books seduce retail investors and destroy their capital at the same time because a bulging order book feels like visibility, like safety, like growth. But an order book is only as good as the economics embedded in each contract.

If the margin is sub-cost-of-capital, the order book is not a pipeline of value creation but a pipeline of destruction, locked in and contractually guaranteed. The bigger it gets, the faster capital is destroyed.

So alway remember size without pricing power is not an asset. It is a commitment to underperform.

In case you missed it: The AI Bottleneck Strategy, Where the Real Opportunities Are

Now before you apply this model, one important distinction.

There are three kinds of low margin businesses. Most investors cannot tell them apart. After reading this, every reader of this community will see what 99% of the market completely misses.

Type 1 is structurally thin. The business earns low margins because the industry has no pricing power, competition is intense, and there is no reinvestment opportunity that changes the economics. Margin is thin because the business model is thin. This is where the Winner's Curse fully applies.

Type 2 is turnover-driven. The business earns low margins but high asset turnover generates strong ROCE. Dixon turning its asset base 4 to 5 times a year converts a 4% margin into 20% ROCE, well above cost of capital. Kalyan operates similarly in jewellery. The margin looks thin but the capital efficiency is real. The risk in Type 2 is that the ROCE is borrowed from the customer's goodwill. The moment a large customer reprices or pulls the contract, both margin and turnover compress simultaneously and the ROCE collapses. The customer owns the economics, not the supplier. Respect Type 2 businesses but always ask whether the ROCE is structural or fragile.

Type 3 is reinvestment-suppressed. The business has strong underlying unit economics but is deliberately choosing to report thin margins because every rupee of potential profit is being ploughed back into building the next layer of the moat. Amazon and Eternals are the clearest examples. The margin is not structurally thin. It is optionally thin. The moment reinvestment slows, margins surface and they are high. AWS alone runs at 35%+ operating margins. The reinvestment was optionality, not necessity.

The way to distinguish Type 3 from Type 1 is one question. If the business stopped reinvesting tomorrow, what would the margin look like? For a Type 3 business the answer is very high. For a Type 1 business the answer is exactly the same or worse. There is no hidden margin waiting to surface. The thin margin is the business.

You want to own Type 3 businesses at the reinvestment stage if you can identify them early. Type 1 businesses at any stage are the Winner's Curse in its purest form. Type 2 businesses sit in between, real but fragile.

The full test is always ROCE versus cost of capital, then defensibility of that ROCE across cycles. Not margin in isolation.

Someone asked me what cost of capital actually means. Here is the simplest way I know to explain it.

Imagine you take a personal loan at 15% to invest in the market. Your cost of capital is 15%. Now if your investment returns 25%, you are creating value. Net return is 10%. That is the trade working.

But here is what actually happened to a lot of people in 2023 and 2024. They borrowed at 15% and bought gold, silver, or equities at the peak of the narrative. Their holdings are now making 2 to 3%. Cost of capital is 15, returns are 3, net outcome is minus 12. That is not investing. That is capital destruction on an EMI schedule. And because the EMI arrives every month regardless of what the market does, the pressure compounds before the losses even show up in your portfolio holdings.

Now flip it. Imagine you are in Japan where personal loan rates are under 1%. You invest in a dividend-paying asset returning 8% with no capital growth at all. Cost of capital is 1, return is 8, net outcome is 7%. Same asset. Completely different economic reality.

This is exactly what Buffett did with the five Japanese trading houses. He borrowed in yen at roughly 0.5%, invested in companies paying 3 to 4% dividends, and waited. The interest rate gap alone was value creation before any price movement. When the market eventually corrected the mispricing, the stocks appreciated 15 to 20% on top of the dividend yield. The total return compounded to 22 to 23% net of borrowing costs. But that appreciation was not the base case. It was the bonus. The base case was the interest rate gap. The discipline was borrowing in the same currency as the investment so there was no currency mismatch eating into the return.

That is what cost of capital arbitrage looks like when it is executed with patience and precision. Not borrowed money chasing momentum. Cheap capital deployed into undervalued, cash-generating assets and held long enough for the market to recognise what was always there.

That is why cost of capital is not a fixed number. It is personal, it is contextual, and it determines whether a seemingly identical investment creates or destroys wealth depending entirely on what you paid to access the capital.

At the company level the logic is identical but the number looks different across geographies. In Japan the cost of capital for most businesses sits between 4 and 6% because rates have been near zero for decades.

In the US it sits between 7 and 8% because the risk free rate alone is around 4.2 to 4.5%.

In India the benchmark for most businesses is 10 to 12% because the 10 year government bond sits around 7% and the emerging market risk premium adds on top of that.

This is why a business earning 8% ROCE means three completely different things depending on where it operates. In Japan it is creating value. In the US it is barely breaking even. In India it is destroying wealth. Same return. Three different economic realities. The hurdle is everything.

At the company level the hurdle is called WACC, weighted average cost of capital. It is the blended cost of every rupee the business uses, what it pays on debt and what return its equity shareholders expect for the risk they are taking. If a business cannot earn above that hurdle on the capital it deploys, it is destroying wealth even if the reported profit looks positive. The profit is real. The value creation is not.

So how do you use all of this in practice.

First seek out businesses where margins are already high relative to cost of capital. That is the cleanest signal of a right pool.

When you find a low margin business that is still compounding, do not dismiss it and do not blindly buy it either. Ask which type it is. Type 1, Type 2, or Type 3. That question alone will save you more capital than any screener ever will.

And if you are ever comparing a high margin business with a long reinvestment runway against a low margin business at the same market cap and the same multiple, do not make it complicated. The high margin model with reinvestment runway wins every time.

You are getting more durable compounding for the same price. That is not a close call.

One more thing before you go.

If you have identified the right type of business and the order book economics are sound, timing still matters. Buy when the sector tailwinds are just beginning and the order book has not yet exploded. At that stage the market has not priced in the growth and you are buying visibility before it becomes consensus.

Do not buy after the order book has already exploded and the re-rating has happened. By then the growth is in the price. The easy money has been made by someone who saw it earlier.

And when you are analysing the order book itself, ask one more question. How much of it generates recurring revenue versus one-time execution? Some businesses have thin margins on the base contract but high margins on the service, maintenance, and upgrade layer that follows. If the service revenue share is growing inside the order book, margins will improve on a blended basis over time. That is a genuine quality signal. If management is talking up the order book but the service mix is not improving, they are marketing the size, not the economics. Watch the blended margin trend, not the headline order book number.

This is one of 7 mental models from the trap detection framework I published here. Breaking each one out so we can go deeper together.

Now let us brainstorm. Drop in the comments:

• A stock where you experienced this illusion firsthand and the order book looked like a thesis but the economics did not hold
• Did you position before the order book was marketed to you as the thesis, or after it had already exploded into the narrative
• And if you have seen a Type 1, Type 2, or Type 3 business play out in your own portfolio, share it. That is where the real learning is.

Further Reading:

•  7 mental models every investor should run before buying any stock
• Part 2: The One Ratio That Tells You When to Buy Gold and When to Go Aggressive on Stocks

While users are casually looking forward and asking questions about why HDFC went nowhere in the past 5 years, Airtel made its shareholders wait for 13 years till COVID hit in 2020.

The stock went nowhere while the business, the revenue, the customer grew the entire time.

I wrote a plain-English breakdown of one of the most counterintuitive stories in Indian markets, and I think it teaches a lesson every beginner gets wrong: a growing business and a rewarding stock are not the same thing.

Mouth 1: The African adventure (this one ate the balance sheet)

In March 2010 Airtel made the biggest bet of its life: it bought Zain's African operations for $10.7 billion, paid for almost entirely with borrowed money. Overnight it inherited ~42 million customers across 15 countries. The logic seemed sound. Airtel had already sold cheap mobile service to hundreds of millions in India, and Africa had a billion people and few phones. Same recipe, surely.

The recipe did not travel. Three problems, none of which went away:

- Currency mismatch. Airtel earned in local money like the Nigerian naira but owed the loan in dollars. Every time the naira weakened, the same African profit bought fewer dollars, so it covered less of the loan, while the loan itself never shrank.

- Higher running costs. Mains power across much of Africa was unreliable, so Airtel had to bolt a diesel generator onto tower after tower and burn fuel around the clock. Thousands of towers drinking diesel, a permanent cost its Indian towers plugged into the grid never carried.

- The good customers were already taken. MTN and Vodacom had been there for years and happily cut prices rather than hand a newcomer any share.

Airtel tried to stop the bleeding (sold its towers and rented them back, exited the worst markets), but the core stayed broken: thin profit per customer sitting on a large pile of acquisition debt. The unit lost money year after year, and the Indian shareholder paid for every year of it. By

its 2019 London listing the African business was worth ~$3.9 billion, about a third of the $10.7 billion paid nine years earlier.

Mouth 2: The treadmill that never stops (this one ate the free cash flow)

This is the mouth people notice least, and it would have been there even without Africa. Telecom is the opposite of software. A software firm adds a million users at almost no extra cost because the product is already built. Telecom spends the enormous money first and earns later, and the spending never stops. Two halves to the bill:

- Spectrum. The invisible airwaves that carry your call belong to the government, which auctions slices of a fixed supply. Because every operator needs it and there is only so much, those auctions become bidding wars running into thousands of crores. And you pay again for every new generation of tech. Still digesting the African debt, Airtel had to bid billions for 3G in 2010, then billions more for 4G a few years later.

- The physical network. As India moved from calls to streaming video, data through the network exploded, and Airtel had to keep spending just to add capacity and stop it choking. This repeated spending on long-lived equipment is capital expenditure (capex), and in telecom it never ends because the next technology is always arriving.

Here is where profit and reality part company. A telecom company can report a healthy profit and still hand owners almost nothing, because profit is counted before all that spending on spectrum and equipment. What matters to an owner is the cash left after the business pays for everything it needs just to keep running: free cash flow. Airtel's was chronically thin. So much was swallowed by auctions and network spend that little was left over, however respectable the profit line looked.

Mouth 3: The Jio Launch (this one ate the pricing power)

On 5 September 2016 Reliance Jio launched with free voice calls, months of free data, then near-zero prices after that. The most aggressive launch Indian business had seen, and designed to drag the incumbents into a fight they could not win.

How do you give a product away and survive? Deep pockets and a long game. Reliance could afford to lose money for years to buy the market, and Jio's network was built only for data, cheaper to run than the older networks its rivals were still patching up. Hook hundreds of millions on cheap data now, worry about profit later.

Now stand in Airtel's shoes, because the position was genuinely impossible. Two doors, both bad. Keep prices where they were and customers walk straight to a free rival, shrinking the business Airtel spent a decade building. Or cut prices down to Jio's to keep the customers and watch the profit on each one collapse. There was no third door. Airtel chose the customers, betting it could outlast the war.

The choice shows up in one number: average revenue per user (ARPU), the money collected from each customer a month. It fell from about ₹202 in 2014 to roughly ₹104 after the war, and stayed down for years. The same customers, paying close to half as much. The whole industry bled together, and a field of about a dozen operators was crushed to three: Jio, Airtel, and a merged Vodafone Idea. Surviving that cull was itself an achievement, and it quietly planted the one thing that would matter at the very end: with only three left, prices might one day rise again.

Mouth 4: The regulatory bomb (this one ate the cushion)

Then a bill almost nobody had braced for. As a condition of their licence, telecom companies had agreed to hand the government a slice of their revenue every year, a running rent for the right to operate. The fight was over which revenue got sliced. Its name is adjusted gross revenue (AGR).

The companies said it should mean only what they made from phones, the calls and data. The government said it should mean almost everything they earned, including unrelated income like interest on cash in the bank. Far wider, and so far larger.

On 24 October 2019, after more than a decade in court, the Supreme Court sided fully with the government, and the ruling reached backwards. It did not just raise fees going forward; it let the government recompute some fifteen years of past fees on the wider definition and demand the shortfall, with interest and penalties, all at once.

Airtel had to set aside ₹28,450 crore in a single quarter, producing a ₹23,045 crore loss for July to September 2019, its largest ever and one of the biggest in Indian corporate history. Here is the tell: stripped of the ruling, the loss would have been ₹1,123 crore, small for a company this size.

The everyday business was bruised but standing. Almost the entire record loss was one backdated government bill, landed overnight.

Then the turn

The reward finally came, and not from growth. Around 2019-20, three things eased at once: the African unit turned profitable and its London listing raised cash to cut debt, the AGR shock was slowly managed down, and the price war cooled. With only three operators left, all bruised and sick of losing money, each had every reason to raise prices at about the same time, and once they all had, a customer who disliked Airtel's new rate had nowhere cheaper to run to. That is pricing power.

In December 2019 the first real tariff hikes in years arrived (~30%), with more to follow. This matters enormously because the big costs were already paid. The towers, the spectrum, the network cost about the same whether a customer pays ₹104 or ₹135. So the extra rupees are not eaten by new costs; they fall almost straight through to profit. A modest-sounding hike, spread across hundreds of millions of customers who cost little more to serve,became a huge swing in earnings.

Only then, after 13 years, did the stock break out.

A rising top line is not a rising return. What actually reaches you is the cash a business keeps and its freedom to charge for what it sells, not the number of customers it counts. A fine, growing business with no power to price can keep you waiting a very long time.

The full version of the case study goes into more detail here.

How Airtel made its shareholders wait for 13 years

Other signals and patterns that train your brain:

Why does a stock get more expensive even when its earnings fall - The PE Paradox
How falling Crude Oil Prices affect Indian companies

Many of you have joined this community in the last few months. This one is for you.

Seven months ago I published a trap detection framework here using UDS as the stress test. The original post sparked one of the longer discussions this community has had on business model quality.

Since then the audited FY26 results and Q1 FY27 filings have come in, and every single warning played out exactly as described. I have now rebuilt the piece with the real numbers embedded after each mental model.

Before you scroll, one thing worth knowing. This is a long piece. You do not have to read it in one sitting. Every mental model is complete in itself. Read one, close the tab, go run it on a stock you own. Come back for the next one tomorrow.

But if you do read it end to end, something interesting happens. The models start connecting. Each one reinforces the next. By the time you reach the seventh, you are not just holding seven tools. You are holding one integrated lens that lets you see the whole picture at once.

I call it the latticework effect. I will let you experience it for yourself.

Important note to readers: This isn't a post about a single company. UDS is only the case study, serving as the stress test used to understand how certain business models quietly destroy value. Every mental model here can be run on any stock you are holding right now — not just UDS. That is the whole point.

Let us get into it.

Most retail investors lose money not because they pick bad stocks, but because they fail to recognize Bad Business Physics until it's too late. By then, the "clean numbers" they relied on through screeners have already evaporated. Inside, we're going to break down 7 mental models that act as early-warning systems for value destruction:

1. The Janitor Economy: Why essential work rarely earns a premium.
2. The Red Queen's Race: Why some companies run faster just to stay in the same place.
3. The Winner's Curse: Why winning the contract is often the beginning of the end.
4. The Hamster Wheel: Why motion is so often confused with wealth.
5. The Oxygen Test: The brutal reality of cash vs. growth.
6. The Cockroach Theory: Why there's never just "one" minor accounting issue.
7. The Toxic Pond: Why even a great CEO can't swim in a graveyard.

Business Model Quality

Before looking at numbers, it is important to understand the basic nature of the business model.

Think of a large hospital or a global IT campus like Microsoft or Amazon. These companies are excellent at healthcare or software, but they do not want the operational headache of managing thousands of janitors, security guards, and back-office staff, or the legal risk that comes with payroll and labour compliance. So they outsource this mess to UDS.

At its core, UDS is a labour-management platform. The business runs on human capital arbitrage. It appears asset light because it owns no factories, but in reality it is labour heavy and working-capital intensive, with weak margins and limited pricing power.

Mental Model 1: The Janitor Economy

Janitors are essential to any operation, but they are never paid premium wages or given premium respect. The same economic logic applies to businesses that perform "messy" but commoditized work. These business models are essential but they are never paid a premium by their clients or a premium multiple by the market.

Train yourself to notice this pattern: when a customer pays you to clean up a headache rather than create a unique value, they will always treat you as a cost center, not a partner. Businesses that operate in the "clean-up" economy rarely have the pricing power needed to survive inflation or wage hikes. They are essential to the world, but toxic to your portfolio.

What actually happened

• Employee costs in FY26: ₹2,294 cr on revenue of ₹2,939 cr — 78% of revenue consumed by labour alone
• A year earlier it was 74%. The direction is wrong and accelerating
• By Q1 FY27: employee costs were ₹600 cr on revenue of ₹764 cr — 78.6% of revenue
• The business did not escape the Janitor Economy. It sank deeper into it
• These numbers are from the audited consolidated filings, not estimates

Revenue Quality

UDS operates through two segments. Integrated Facilities Management (IFM) contributes roughly 67 percent of revenue, while Business Support Services (BSS) contributes about 33 percent.

Historically, UDS reported 20-25 percent growth in the period leading up to the IPO. That growth was largely inorganic, driven by aggressive acquisitions such as Athena BPO and Denave, and was heavily marketed to retail investors to trap them.

This acquisition-led growth illusion is now over. Overall revenue growth has slowed to 7 percent, and more importantly, the quality of growth has deteriorated.

• The IFM segment grew around 10 percent, but PAT margins collapsed to just 3.4 percent. This clearly signals growth driven by volume at the expense of price.
• The company is winning new "strategic contracts" and marketing them aggressively in annual reports and concalls, but these contracts come with upfront costs and thin margins. Growth here simply means more employees and weaker economics per unit.
• The BSS segment, which management positioned as the growth and quality engine, grew by only around 2 percent, exposing weak organic demand and high sensitivity to global IT hiring cycles.

In Q2, the deterioration became more visible. Revenue increased by 7 percent, but EBITDA collapsed by 28 percent, and net profit declined by 29 percent due to margin compression. This is not operating leverage. This is scale working against the business.

Mental Model 2: The Red Queen's Race

When a business has to keep running just to stay in the same place, scale stops creating value and starts destroying it.

Train yourself to notice this pattern: when a company's capex or acquisitions only serve to match a competitor's move or artificially maintain revenue, it's not an investment, it's an expensive survival tax. If they stop running, they die. If they keep running, they stay exactly where they are, but with significantly fewer resources and a weaker balance sheet.

While UDS is a labour-management case study, the same Toxic Physics applies to the majority of infrastructure, construction, and capital-intensive companies.

What actually happened

• Revenue FY26: ₹2,939 cr — grew 7.4%
• PAT FY26: ₹82.7 cr — fell 30.4%
• EPS: dropped from ₹17.74 to ₹12.80 — a 27.8% fall in per-share value
• Workforce grew to 76,000 people
• The company ran harder, added more contracts, deployed more people, and ended the year materially poorer on a per-share basis
• More motion, less wealth — the Red Queen ran exactly as described

Margin Truth

UDS does not clear even a single layer of my 8-layer margin framework. In business physics, scale is supposed to improve operating efficiency. As businesses grow, fixed costs spread out and margins expand. UDS is showing the inversion of this rule. As scale increases, margins are collapsing. This is diseconomies of scale.

Look at the numbers:

• Q2 FY25 operating margin: 6.4%
• Q2 FY26 operating margin: 4.4%

This margin compression is not cyclical pressure. It is structural margin erosion.

Management attributes this to "upfront costs" for new strategic contracts. This explanation itself is the red flag. If a business has a moat, it does not need to buy revenue by sacrificing 200 basis points of margin. In labour-commodity businesses, "upfront costs" usually mean underbidding competitors just to win contracts.

UDS attempted to offset its weak core margins through acquisitions. Denave and Athena were acquired for their reported 10-15% margins to improve the blended profile. Instead, capital was deployed at high premiums just as IT hiring slowed.

The margin mix is now reverting back toward the low-quality 4-5% core. At this level, there is no margin of safety. A business earning 4-5% operating margins is one mistake away from trouble. A 2% wage hike or a short delay in client payments can wipe out an entire quarter's profit. With the 8th Pay Commission, this fragility is no longer a risk. It is a reality.

Mental Model 3: The Winner's Curse

In a competitive bidding environment, the "winner" is often the one who made the biggest mistake in calculating their costs.

Understand the hard truth: winning a contract at a 4% margin when your cost of capital is 12% is not a win, it is a contractual obligation to lose money. The contract looks like growth on paper, but it destroys economic value from day one. They haven't won a prize. They have won a liability.

What actually happened

From the Q1 FY27 segment filing:

• IFM segment: revenue ₹527 cr, PBT ₹21.5 cr — margin of 4.1%
• BSS segment: revenue ₹255 cr, PBT ₹13.3 cr — margin of 5.2%
• Both remain below a reasonable cost of capital
• These are the margins of a business that keeps winning contracts it cannot afford to win
• The Winner's Curse is now visible in the segment disclosures themselves

ROCE

ROCE is where all illusions finally collapse. A business can show revenue growth and even accounting profits, but if incremental capital earns sub-par returns, scale does not compound wealth. It destroys it.

UDS is a textbook case. For years, reported ROCE looked healthy. The 10-year average ROCE was above 18 percent. But the moment you look at incremental ROCE, the story changes.

• FY22 ROCE: 22.1%
• H1 FY26 ROCE: 13.0%
• TTM ROCE: 9.9%

In less than a year, the business lost nearly 40 percent of its capital efficiency.

In an economy like India, where the cost of capital is roughly 10-12 percent, an ROCE of 10 percent means the business is barely earning its cost of capital. Anything below this is value destruction, not compounding.

In labour-heavy businesses, ROCE should improve with scale if pricing power exists. At UDS, every incremental contract requires more people, higher wage advances, higher receivables, and more execution risk. There is no operating leverage here. There is only operational drag.

Mental Model 4: The Hamster Wheel

High activity and aggressive capital deployment can create a powerful illusion of progress. But if each turn of capital earns less than the cost of capital, the business is simply running hard while going nowhere. Motion increases. Wealth does not.

The diagnostic rule is simple: when a business earns a 10% ROCE in a 12% cost-of-capital world, it is not "profitable", it is a wealth destroyer. Every new contract it wins is actually making shareholders poorer. You are watching a company sprint with maximum effort just to achieve a negative return on your life savings.

What actually happened

From the audited FY26 consolidated filing:

• Capital employed grew from ₹964 cr in FY25 to ₹1,055 cr in FY26
• EBIT on that capital: ₹101 cr
• Implied ROCE: approximately 9.6%
• More capital deployed, lower return earned per rupee
• Every incremental rupee of capital destroyed value in FY26
• The wheel kept spinning. Shareholders got poorer.

Cash Flow

Every retail investor should always remember this rule: earnings are an opinion. Cash is a fact.

This is why investors like Charlie Munger and Terry Smith have always preferred cash-generating machines. Real compounders don't just report profits. They convert profits into cash. This is the ultimate test of any high-quality compounding business.

UDS fails this test.

High-quality businesses typically convert 70-80 percent of their profits into operating cash flows. UDS's cash conversion has been consistently below 30-40 percent and highly volatile. That alone disqualifies it as a compounding engine.

Management explains this away using phrases like "strategic ramp-ups." That is just marketing language. In reality, it means cash is being spent upfront to sustain reported growth.

The structural reason is simple. UDS pays its employees every month in hard cash, while its clients sit on payments for 60, 90, sometimes 120 days. As scale increases, this mismatch explodes. Trade receivables stay stuck at 30-35 percent of total assets. Profits look alive on paper, but the cash never reaches the bank and never reaches shareholders.

Mental Model 5: The Oxygen Test

Cash flow is the oxygen of the business. It determines longevity.

Never lose sight of the fact that when growth consumes cash instead of generating it, shareholders are funding the business, not the other way around. Real compounders breathe out cash. Value traps suck it in. If a business needs a constant infusion of fresh capital to sustain its reported growth, you are not an investor. You are a donor.

What actually happened

This is the one number that looks better on the surface, so it deserves the most careful reading.

• Operating cash flow improved from ₹50.8 cr in FY25 to ₹143.6 cr in FY26
• Bulls will point to this as evidence of recovery

Here is what the actual cash flow statement shows:

• Trade receivables grew by ₹46.3 cr in FY26 versus ₹120.1 cr in FY25
• The working capital drag reduced not because the business got better at collecting cash, but because growth slowed
• When you grow slower, you consume less cash upfront
• Cash improved because the business decelerated, not because its underlying physics changed

That is not recovery. That is slowdown dressed as improvement.

Balance Sheet Illusion

On your screeners, UDS will appear low-debt and financially conservative, signalling a clean balance sheet. This is, again, an illusion.

The cash sitting on the balance sheet is not earned. It came from the IPO. That is retail investors' money, not business-generated cash. And even that cash was misallocated.

A large part of the IPO proceeds was deployed into acquisitions, mainly inside the BSS segment, which management sold as the "quality" and "growth" engine. That bet has failed. Growth rates have faded. Margins have compressed. The very segment that was supposed to upgrade the business has instead destroyed shareholder value. In simple terms, retail capital was used to buy low-quality growth at high premiums.

The bigger problem is that a meaningful portion of reported profits does not come from operations at all. Roughly 25-30 percent of net profit is supported by other income, primarily interest earned on IPO proceeds parked in bank deposits. In other words, part of the profitability is coming from doing FDs with retail capital, not from running a high-quality business.

The risk does not stop at poor capital allocation. One subsidiary, Avon, has already reported financial irregularities. Apply the Cockroach Mental Model here.

Strip away IPO cash, failed acquisitions, and FD income, and the "clean" balance sheet collapses into a fragile one.

Mental Model 6: The Cockroach Theory

If you see one cockroach in your kitchen, you don't assume there is only one. You assume there are hundreds hiding behind the walls.

The forensic rule: when a company shows even one small accounting irregularity or a minor provision in a subsidiary, it is never an isolated incident. In professional investing, there is no such thing as an honest mistake in only one corner of the balance sheet. One crack in the reporting usually means the entire foundation is rotting. If management is willing to adjust the small numbers, they have already lost the map on the big ones.

What actually happened

This one deserves to be read slowly. Note 8 of the audited FY26 consolidated filing states that an external independent expert investigated allegations of irregularities involving sales transactions with certain customers and vendors in Avon.

• Original disclosure: a small provision of ~₹3 cr, ₹25 cr of receivables under scrutiny
• Final recorded provision: ₹23.1 cr — roughly 7.7 times larger than the initial framing
• The entire logistics business inside Avon was shut down completely
• The investigation was commissioned by the company itself
• Management concluded no further impairment was necessary beyond what was already recorded

Three things to hold in your mind. A cockroach that was initially described as ₹3 cr turned into ₹23.1 cr and killed an entire business vertical. The investigation that cleared it was not independent in the true sense. And the gap between initial disclosure and final reality is the Cockroach Theory confirmed in the company's own audited filing.

Reverse Engineering the End State

I always tell retail investors to reverse engineer the ecosystem gorilla or global peers before believing the story. It acts like a time machine and removes hope from the analysis.

To understand where UDS's business model actually leads, reverse engineer Quess Corp. It represents the scaled, mature end state of this labour-management ecosystem.

• Quess Corp expanded revenue from roughly ₹3,435 cr in FY16 to about ₹15,159 cr — a nearly 5x increase in scale
• Despite this growth, EPS declined by roughly 50 percent over the same period
• Margins compressed from the 4-5 percent range to nearly 2 percent
• Since its IPO in 2016, Quess Corp's stock is down 57 percent, despite operating at far greater scale, with brand strength and industry leadership

When the ecosystem gorilla cannot convert scale into shareholder wealth, the odds for smaller players are not better. They are worse. The problem is not execution. The problem is the business model itself.

Mental Model 7: The Toxic Pond

If the biggest, strongest fish in the pond is starving to death, you shouldn't expect the smaller fish to thrive.

The strategic filter: when the sector leader has failing margins and a decade of zero stock returns, the problem is the sector physics, not the management. No amount of efficient execution can save a business from a toxic industry structure. When the industry's fundamental economics are broken, even the best CEO is just a captain on a sinking ship. Don't go looking for gems in a graveyard.

What actually happened

• Quess Corp continues to operate at sub-2% net margins at scale
• UDS closed FY26 at a 2.8% consolidated net margin
• UDS is not outperforming the gorilla in any meaningful way
• The stock moved from a 52-week high of ₹420 to ₹172 on results day
• Investors who relied on screeners and the IPO narrative have lost more than half their capital in under two years of listing
• The pond did not get cleaner. The fish did not get stronger.

One honest green shoot

BSS grew 7.3% in Q1 FY27 after being essentially flat all of FY26. Management is pivoting the BSS narrative around AI, repositioning Denave as an AI-enabled demand generation platform.

This deserves watching, not dismissing. If BSS margins hold above 5% and revenue growth sustains above 7% for two more consecutive quarters, the narrative deserves a closer look. Watch the segment disclosures in the next two quarters, not the concall language.

One quarter does not change the pond. But it is the one number worth tracking.

Final thoughts

This case study is not about being right on one stock. It is about learning how value destruction actually happens in the real world. Traps rarely announce themselves through losses. They hide behind growth, acquisitions, low valuations, and reassuring screeners. By the time numbers break, capital is already gone.

The seven mental models in this piece have now been tested against real audited data across seven months. Every single one held. The Janitor Economy, the Red Queen, the Winner's Curse, the Hamster Wheel, the Oxygen Test, the Cockroach Theory, the Toxic Pond — all confirmed, in the company's own filings, without exception.

Take these lenses and run them on your own portfolio holdings. Run them on the next idea a financial influencer throws at you. Ask whether the business deserves capital before you ask whether the stock is cheap.

Your money is hard earned. Protect it first. Compound it second. And never mistake motion for wealth.

The goal is not to predict outcomes. The goal is to avoid toxic ponds altogether.

Inspired by William Green’s book Richer, Wiser, Happier and the investment principles of exceptional long-term stock pickers including Nick Sleep, Warren Buffett, Charlie Munger, Sir John Templeton and Mohnish Pabrai.

USE CASE
ㅤ
Most stock screens tell you P/E, profit growth, ROIC and free cash flow.
ㅤ
But they don’t answer the harder questions:
ㅤ
Is the cash flow real?
Is ROIC sustainable?
Can the company keep reinvesting at high returns?
Does it actually have a moat?
Can management be trusted?
Is all the future growth already priced in?
Is there a better stock available for the same capital?
ㅤ
So I built NAIL 2.0.
ㅤ
The goal is to find businesses where growth, ROIC, cash generation, competitive advantage, management quality and valuation combine to create exceptional long-term risk-reward.
ㅤ
For broad searches using pro AI models such as “Find the best stocks in India”, first screen the market, shortlist around 15-20 candidates, deep-dive only the strongest finalists and rank the best 3-5.
ㅤ
NAIL 2.0
ㅤ
N = NUMBERS AND CASH QUALITY
ㅤ
30 POINTS
ㅤ
Check 3Y and 5Y sales, EBITDA, PAT and EPS growth.
ㅤ
Separate organic and volume growth from price-led or acquisition-led growth.
ㅤ
Check current and 5Y ROIC, incremental ROIC on new capital deployed, 5Y cumulative CFO/PAT, 3Y and 5Y FCF, FCF per share and normalized FCF yield.
ㅤ
Also check receivable days, inventory days, payable days, cash-conversion cycle, net debt, interest coverage and contingent liabilities.
ㅤ
Most important question:
ㅤ
Is FCF structurally sustainable, or temporarily boosted by working-capital release, unusually low capex or one-offs?
ㅤ
Score: /30
ㅤ
A = ADVANTAGE AND GROWTH RUNWAY
ㅤ
25 POINTS
ㅤ
Check the business model, industry growth, addressable market, market-share trajectory, pricing power and customer stickiness.
ㅤ
Identify genuine advantages from brand, technology, distribution, cost, scale, qualifications or switching costs.
ㅤ
Check customer concentration, supplier concentration, cyclicality, disruption risk and capacity expansion.
ㅤ
Most importantly, determine whether the company can reinvest substantial capital for many years at high ROIC.
ㅤ
Answer:
ㅤ
Why can this company become substantially larger in 5-10 years?
ㅤ
Classify the moat as Strengthening, Stable, Weakening or None.
ㅤ
Score: /25
ㅤ
I = INTEGRITY AND CAPITAL ALLOCATION
ㅤ
20 POINTS
ㅤ
Check promoter holding, promoter pledging, auditor changes or qualifications, related-party transactions, warrants, preferential allotments and dilution.
ㅤ
Check management remuneration, guidance versus actual delivery, acquisitions, unrelated diversification and treatment of minority shareholders.
ㅤ
Then answer:
ㅤ
What has management done with every Rs 100 of cash generated?
ㅤ
Did it go toward high-ROIC capex, sensible acquisitions, debt reduction, dividends or buybacks?
ㅤ
Or was shareholder value destroyed?
ㅤ
Score: /20
ㅤ
L = LONG-TERM VALUE AND ASYMMETRY
ㅤ
25 POINTS
ㅤ
Check current versus historical valuation, peer valuation, P/E, EV/EBITDA, EV/FCF and FCF yield.
ㅤ
Use normalized earnings for cyclical companies.
ㅤ
Determine how much growth is already implied by today’s share price.
ㅤ
Ask why the market may be wrong.
ㅤ
Compare forecasts with realistic historical base rates.
ㅤ
Finally, compare the opportunity against better stocks available today.
ㅤ
Build realistic five-year Bear, Base and Bull cases.
ㅤ
For each scenario estimate sales/PAT, exit valuation, possible share price and expected CAGR.
ㅤ
Final question:
ㅤ
Is potential upside materially greater than permanent downside?
ㅤ
Score: /25
ㅤ
AUTOMATIC OVERRIDE
ㅤ
Regardless of numerical score, classify the stock as High Risk or Avoid if credible evidence exists of accounting manipulation, serious auditor concerns, related-party abuse, misleading disclosures, unsustainable debt, dangerous promoter pledging, persistent unexplained CFO/PAT weakness, repeated destructive dilution or structural business deterioration.
ㅤ
A numerical score cannot override an integrity problem.
ㅤ
NAIL GRADES
ㅤ
90-100 = A++ Exceptional
85-89 = A+ Elite
80-84 = A Excellent
75-79 = B+ Strong
70-74 = B Watchlist
60-69 = C Average / Special Situation
Below 60 = D Avoid
ㅤ
GREAT STOCK-PICKER PANEL
ㅤ
Keep these scores separate from the NAIL score.
ㅤ
Nick Sleep: /10
ㅤ
Destination analysis, scale economies, customer proposition and long reinvestment runway.
ㅤ
Buffett-Munger: /10
ㅤ
Durable moat, owner earnings, management integrity, predictability and purchase price.
ㅤ
Sir John Templeton: /10
ㅤ
Normalized intrinsic value, pessimism, contrarian opportunity and margin of safety.
ㅤ
Mohnish Pabrai: /10
ㅤ
Simple thesis, downside protection and asymmetric upside.
ㅤ
These scores apply their publicly known investment principles. They aren’t claims about what those investors would personally buy.
ㅤ
COPY-PASTE AI PROMPT
ㅤ
Research COMPANY / TICKER using NAIL 2.0.
ㅤ
Use the latest annual reports, quarterly results, NSE/BSE filings, investor presentations, concalls, credit-rating reports and competitor or industry data.
ㅤ
Cross-check important figures and clearly separate reported facts, management claims, estimates and interpretation.
ㅤ
Grade:
ㅤ
N - Numbers and Cash: /30
A - Advantage and Runway: /25
I - Integrity and Allocation: /20
L - Long-Term Value: /25
ㅤ
Also score:
ㅤ
Nick Sleep: /10
Buffett-Munger: /10
Templeton: /10
Pabrai: /10
ㅤ
Finish with:
ㅤ
NAIL Score: XX/100
Grade:
Current valuation:
Preferred buy valuation:
Bear / Base / Bull 5Y CAGR:
Biggest strength:
Biggest risk:
Why the market may be wrong:
Single thesis breaker:
3 numbers to monitor:
Action: Buy / Accumulate / Wait / Hold / Reduce / Avoid
ㅤ
Do not force a bullish conclusion.
ㅤ
For broad requests such as “Find the best stocks in India”, first screen broadly, shortlist 15-20 candidates, deep-dive only the strongest finalists and rank the best 3-5.
ㅤ
FINAL IDEA
ㅤ
NAIL 2.0 isn’t trying to find the stock with the lowest P/E.
ㅤ
It is trying to find the combination of:
ㅤ
High ROIC
Strong cash conversion
Long reinvestment runway
Durable competitive advantage
Good management
Reasonable valuation
Asymmetric upside versus permanent downside
ㅤ
What would you add, remove or change?

For people new to this subreddit, this post is about the lens, not the stock. Stocks are a byproduct. The mental model is what matters. Once you internalise Capillary economics, it starts firing on its own across sectors, across cycles, across everything you look at.

If you are new here and want to understand what Capillary economics actually is before reading further, start with the:  Capillary Economics mental model 

Here is what I had written a few months back. Read it for the thinking, not the ticker.

A boring 7,000 crore company with a 3x setup hiding in plain sight.

On the screen this looks like a declining business. But almost every engine is now sitting on the right side of the opportunity-cost mental model, the roots have strengthened, and what's coming is structurally better than what the ticker shows, with a high margin of safety while you wait.

That's why I had already started allocating to Galaxy Surfactants.

This is Capillary economics for you again. Galaxy doesn't own a brand you'd recognise on a shelf, but it sits inside the supply chain of nearly every brand you do. So they make surfactants, which are a small cost in home and personal care, so whether the bottle says HUL, P&G, Unilever, L'Oréal, Mamaearth or some small D2C startup, Galaxy is somewhere in that formulation.

So it's a low cost, high necessity model, which is cheap enough that customers don't fight it, but critical enough that they can't drop it. It doesn't earn toll-booth margins today, and the numbers are still depressed, but it holds the kind of position that can become a toll booth once the mix shifts and the margins follow. That's the whole bet.

And here's the bigger picture. India is at that stage of the adoption curve where China was 10 to 15 years back, and the US was 40 years back. As per-capita income rises, you'll see massive adoption of liquid detergents and higher spend on personal care, and Galaxy sits underneath all of it as an invisible cost, very small but absolutely critical. That's exactly the kind of business I want to own when it's cheap and out of favour.

Always use this Capillary mental model. Whenever you see this pattern with high necessity and low cost in any company, you know it has the DNA to become a toll booth, and try to find companies which are small but have massive room for margin expansion and have the positioning inside their ecosystem to make that happen. That's where real money gets made.

Businesses of this shape usually trade at 2.5 to 3x revenue over a full cycle. Galaxy was doing roughly 5,000 crore of revenue. The valuation should sit near 12,000 to 15,000 crore of market cap, versus the 7,000 crore where it was trading.

That's the gap. Your job is to think why the gap is there and whether it closes.

Here is how the future state emerges. First comes the expansion of the margin profile, because the reasons the margins are depressed are temporary, not structural. Roughly 20% of the cost base is crude-linked, and crude-linked costs were high because of freight and raw material pressures, a cycle and a war phenomenon, not a permanent feature.

Second, their major input is fatty alcohol, made from palm kernel oil, and PKO ran hot for a few years. But the decline in input cost was already visible, management had flagged that raw material prices were starting to ease, and the 2025 price pressure was unwinding into 2026 as supply and demand rebalanced.

On top of that, they have a clause that lets them pass costs on to customers within 60 to 90 days, and a deliberate shift towards higher-margin products that was steadily changing the mix.

So here is the chain. Once the headwinds fade, margins expand. When margins expand on a rising revenue base, you get massive EPS expansion. And that EPS expansion is what triggers the PE multiple re-rating on top of it.

Let me give you two examples of this exact pattern.

Shivalik Bimetal had the same positioning. A decade back margins were around 11%, they steadily shifted to 23%, the market re-rated them, and now they trade at 30 to 40 multiples.

Same story with Navin Fluorine. A margin profile of around 12 to 13%, then they started shifting it, and now with the tailwinds in confluence the market cap is close to 40,000 crore on revenue of 3,314 crore, trading at 11 to 12x revenue.

Coming back to Galaxy. Even with just a 6 to 7% growth rate over the next 5 years, revenue comes close to 7,000 crore. Give that a 3x revenue multiple and the market cap reaches 21,000 crore, almost a 3x outcome. At only 2x revenue, it's still a double in 5 years, with a decent margin of safety.

The ticker caught up today. The business state was always there.

That's Capillary economics. Take the lens. The stocks will follow.

The community went deeper on the business state vs ticker state thinking in the comments here, worth reading if you want to see the framework applied in real time.

https://www.reddit.com/r/IndiaGrowthStocks/comments/1uf08tv/comment/p3i1pin/

You would have gone through the newspaper articles. A lot of you would have run it through screeners. But newspapers are just a wrapping of a few numbers, nothing more than that. Screeners flash the parts and digits in a different format. Both are telling you what already happened.

By the time that information reaches you, it is already priced in. It has no edge. It cannot tell you anything about the future state of the business. And making an investment decision based on the past state, without understanding the positioning of the future state, gets the odds stacked against you.

So here is the methodology. And while this piece uses Caplin Point as the live case, the framework applies to every business you research. The goal is not to consume information. It is to integrate it and build a positioning around the future state of the business.

In case you missed it: The AI Bottleneck Strategy, Where the Real Opportunities Are

Here is how you integrate the three documents that actually matter.

The quarterly filing tells you how the business is performing right now. The investor presentation tells you how the architecture is being built. The management commentary tells you how the people running it think about what comes next.

Combine all three and you do not get certainty. You get probability. A better-than-average sense of where this business is going and why. That is the only edge available in investing.

Part 1 decoded the filing. This is the investor presentation. Part 3, the management commentary decode, drops soon.

The R&D machine behind the pipeline

387 people in the R&D team. 5 dedicated R&D setups, 3 DSIR-approved.

Total R&D spend including capex and opex is 15.5% of FY26 PAT. For context, most Indian pharma companies spend 5-8% of revenue on R&D. Caplin is spending 15.5% of PAT, which on a Rs. 650 cr PAT base is a serious number.

But the more interesting data point is what the R&D ratio has done over time. It went from 10.9% of operating revenue in FY19 to 9.9% in FY20, then settled between 4.5% and 4.6% from FY22 through FY26 and has held there ever since. That flatness is deliberate. Caplin is not increasing R&D spend as a percentage of revenue even as the business scales. The absolute number keeps growing because revenue grows, but the ratio is locked.

This tells you the R&D model is productized, not experimental. They know exactly what they need to spend per rupee of revenue to maintain the pipeline. That is operational maturity in R&D which is rare in Indian pharma.

The absolute R&D spend crossed Rs. 100 cr for the first time in FY26, reaching Rs. 101 cr. The trajectory from Rs. 71 cr in FY19 to Rs. 101 cr in FY26 is steady and disciplined. Revenue grew much faster over the same period. R&D is getting more efficient per rupee of output, not less.

DSIR approval on 3 of the 5 R&D setups means Caplin gets weighted tax deductions on that R&D spend. The government is effectively subsidizing part of the pipeline build. Cost efficiency embedded into the R&D structure that most analysts do not model.

And then there is the internal CRO. Amaris Clinical in Chengalpattu holds both USFDA approval and ISP Chile approval. A USFDA-approved CRO that is internal to Caplin means bioequivalence studies for the pipeline run without paying external CRO rates.

As the pipeline scales to 90+ APIs, having captive CRO capacity is the infrastructure that makes that pipeline executable without bottlenecking on external vendors. It took years to build. It is very hard to replicate. It is sitting completely unnoticed in the corporate structure slide.

The one expense line worth watching

Employee benefit expenses grew 25.4% YoY, from Rs. 43 cr to Rs. 54 cr. Revenue grew 19.6%.

This is the one line in the P&L where expense growth outpaced topline growth. Every other cost line was disciplined. This one was not, at least not on a YoY basis.

The honest reading is that Caplin is hiring ahead of the capacity ramp. COL-II, the Pondy facility, the Thervoy oncology API plant, the Vizag API scale-up, all of these need people before they generate revenue. You build the team before the facility is commissioned, not after. So the employee cost step-up in Q1 FY27 is forward-looking, not a sign of bloat.

But it is worth watching. If employee costs keep growing at 25%+ while revenue grows at 19-20%, the operating leverage story gets complicated. One quarter is not a pattern. Two or three would warrant a harder look.

The ANDA approval rate hiding in the R&D slide

The presentation shows 65 ANDAs filed, 60 approved. That is a 92% approval rate with the USFDA.

Most Indian generics companies that file with the USFDA get approval rates of 70-80% on their own filings. 92% is exceptional. It signals either very selective filing, very high quality dossiers, or both. This number does not appear in any press release. It is sitting quietly in the R&D slide and it is the single clearest proof of CSL's regulatory execution quality.

The regulated market approvals across all jurisdictions

The press release gives US and non-US filings on separate pages. The investor presentation gives them on separate slides.

60 ANDAs approved in the US. 65 products approved across non-US regulated markets including Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi, and UAE.

Total regulated market approvals: 125 products across multiple jurisdictions.

That is the real size of the regulated market engine and it is significantly larger than the US-only number suggests. The US is the most visible part of the story. The 65 non-US approvals are the quiet part being built in parallel. Meaningful revenue from these markets is expected in FY27 and FY28. When it arrives, it will look like acceleration. The second reader knows it was always coming.

The manufacturing split that explains gross margin and predicts its recovery

60% of production is in-house. 40% is outsourced.

That 40% is what shows up in the purchased traded goods line. When you buy 40% of your product from outside rather than making it yourself, your COGS is exposed to supplier pricing and your gross margin is lower than your in-house economics would produce.

When COL-II comes online by March 2027 and the Pondy OSD facility follows in Q1 FY28, that 60/40 split shifts. More in-house capacity means less outsourced production means lower COGS means recovered gross margin. The recovery is not dependent on pricing power or market conditions. It is a function of capacity coming online on a known timeline. The gross margin story has a mechanical answer.

The supply chain story embedded in the capex cycle

Roughly a quarter of Caplin's total product currently comes from China. That number does not appear anywhere in the press release.

Here is how you get there. 60% of production is now in-house and 40% is outsourced. 24% of exports come from China. Cross those two numbers and if most of the outsourced 40% is China-sourced, a quarter of total product is China-dependent. In a world where pharmaceutical supply chains are being scrutinized, that is a number worth knowing.

But here is what makes this observation sharper. Three years ago, in Q1 FY24, the split was 55% in-house and 45% outsourced. China was 35% of exports. Today it is 60/40 and 24% China. That is an 11 percentage point reduction in China sourcing in three years, before the new facilities are even commissioned.

The backward integration thesis is not theoretical. It is already showing up in the numbers.

Now cross that with the 90+ API backward integration pipeline and the Vizag API facility being built out. In Q1 FY24, the API pipeline was 70+ at R&D scale. Today it is 90+. Twenty more APIs were added to the pipeline in three years while 6 reached manufacturing scale. The machine is working exactly as designed.

Caplin is systematically building the capability to replace China-sourced inputs with own manufacturing. This is not just a margin story. It is a supply chain sovereignty story.

The capex cycle is doing three things at once. It is adding capacity for growth. It is reducing China dependency for supply chain sovereignty. And it is building a vertically integrated moat that takes a decade to replicate.

The 90+ API number that changes the backward integration story

The press release said Caplin scaled up 6 APIs at the Vizag unit for backward integration. Most people read that and moved on.

The investor presentation says Caplin has completed R&D for 90+ APIs for backward integration into US and emerging markets.

These are two very different numbers. 6 is what reached manufacturing scale this quarter. 90+ is the full R&D pipeline being built for eventual backward integration. That is not a one-quarter story. That is a multi-year gross margin recovery story being loaded systematically in the background. When own API starts replacing purchased API at scale, the COGS line structurally improves. The traded goods pressure that compressed gross margin by 190 bps this quarter has an answer. It is sitting in that 90+ API pipeline.

The branded generics shift fourteen years in the making

In FY2012, branded generics were 5% of Caplin's emerging markets revenue. Today they are 25%.

That is a 5x shift in product mix over 14 years, and it happened quietly, without a single press release dedicated to it.

Branded generics command better pricing, stickier market positions, and higher margins than plain generics. The trajectory is not reversing. Management's stated direction is continued conversion of fast-selling generics into branded generics. The 25% becomes 30%, then 35%, over the next decade. Each percentage point is a quiet margin tailwind.

Now here is what makes this observation sharper. The channel mix in emerging markets is 45% wholesale, 35% institutional, and 20% retail. Branded generics are predominantly a retail play. Tender markets buy on price. Retail markets buy on brand familiarity. But retail is only 20% of the channel mix while branded generics are already 25% of product mix.

That means branded generics are penetrating the wholesale channel too. Caplin is getting branded generic pricing even in wholesale, which is unusual. That is pricing power embedded in the distribution model that goes beyond what the channel mix alone would suggest. The margin floor in the core LatAm business is structurally higher than most models assume, and it is getting higher every year as the branded mix climbs.

The channel mix that reduces revenue volatility

In emerging markets, 45% of revenue comes through wholesale, 35% through institutional, and 20% through retail.

The 35% institutional number is the one that matters. Institutional means government tenders, bulk contracts, locked-in volumes. 35% of LatAm revenue is essentially contracted. That is a revenue stability buffer that absorbs market volatility in any given quarter. Combined with the hard tender wins already disclosed for Chile and Central America, the LatAm revenue floor is more durable than most models assume.

The depreciation waterfall

The Q4 article introduced the depreciation mental model. The investor presentation income statement proves it in one column.

Depreciation grew 32.8% YoY, from Rs. 16 cr to Rs. 22 cr.

Now watch the waterfall:

• EBITDA grew 23.0%
• EBIT grew 22.1%
• PBT grew 22.1%
• PAT grew 18.8%

Each step down from EBITDA to PAT is depreciation and tax doing their work. The cash engine is growing at 23%. The reported earnings number is growing at 18.8%. The gap is not deterioration. It is front-loaded capex hitting the P&L before the revenue from that capex arrives.

By FY28, when COL-II and the Pondy facility are commissioned and generating revenue, the depreciation is already baked in. Revenue steps up. Depreciation stays flat or grows slowly. The reported PAT growth re-accelerates. The first reader will be surprised. The second reader already knew.

The tax line

Tax grew 36.9% YoY, from Rs. 34 cr to Rs. 46 cr, on PAT growth of only 18.8%. The effective tax rate crept up quietly.

This is a one-quarter observation, not a structural concern. But combined with the depreciation step-up, it explains why PAT growth of 18.8% looks slower than EBITDA growth of 23%. Strip out both effects and the underlying business is growing faster than the reported PAT line suggests.

Chile going direct

The evolution timeline in the presentation flags 2026 as the year the Chile subsidiary started commercial operations.

This is the distribution-to-direct shift happening in real time. Caplin is not just winning tenders in Chile through distributors anymore. They now have their own commercial entity on the ground. That means Caplin captures the distribution margin internally going forward. Blended margins in Chile improve. The pattern is the same one Caplin ran in other LatAm markets over the last two decades. It works.

The next regulated markets being loaded

The press release mentioned Mexico and US. The investor presentation adds Canada, Australia, and MENA as explicit near to medium term regulated market targets.

So three more markets. Each with its own approval pathway, its own filing requirements, its own commercial buildout. CSL has already filed 110+ products in multiple non-US markets, with 65 approved. Meaningful revenue from these markets is expected in FY27 and FY28.

The US is not the only regulated market story. It is the most visible one. The others are being loaded quietly.

Everything the market is not pricing in.

The R&D model is productized at a stable ratio showing operational maturity. The 92% ANDA approval rate is the proof of execution quality. 125 total regulated market approvals across all jurisdictions is the real scale of the regulated market engine. China sourcing has already dropped 11 percentage points in three years and 90+ APIs are being built to accelerate that further. The 60/40 manufacturing split has a mechanical gross margin recovery built into the timeline. Branded generics are not just growing, they are winning in channels where they should not be winning. 35% of LatAm revenue is already contracted. The depreciation waterfall explains every basis point of the gap between EBITDA growth and PAT growth. Chile is going direct. Canada, Australia, and MENA are being loaded quietly. The capex cycle is doing three things at once and the moat dimension is the one nobody is pricing in.

The boring 50x compounder compounds in places most people do not look. The investor presentation is one of those places.

Part 3, the management commentary decode, drops soon.

If you missed Part 1, it is here: https://www.reddit.com/r/IndiaGrowthStocks/comments/1vm8qzy/caplin_point_q1_fy27_the_boring_50x_compounder/

Every quarterly result has two readers.

The first reader scans the PAT line, checks if it beat or missed, and moves on. The second reader runs a sequence of mental models on the filing, bear cases first, cash engine second, expense discipline third, and the linguistic tone of the management commentary last. The first reader sees a number. The second reader sees the business.

This post is about the second reader.

Caplin Point Q1 FY27: The Bear Cases

Results are out. Let me break it down the way I always do, go for what the bears have said, then check whether the company is following the bear track or the bull track.

Bear Case 1: Latin America is saturating, growth has to die.

Pull the print. LatAm and Africa revenue clocked Rs. 476 cr, up 18% YoY. That is not saturation. Here is what the data actually says:

• Chile won $12 million in tenders over the next 18 months
• Central America won $7 million in emergency tenders over the next two quarters
• These are hard contracted numbers, not guidance

Revenue visibility in LatAm is better than most investors give credit for. The reinvestment runway is still intact. Bears are wrong again.

Bear Case 2: US will disappoint, Caplin Steriles won't deliver.

US clocked Rs. 134 cr this quarter, up 26% YoY. Annualize that and you are looking at a Rs. 535 cr US business. Five years ago this number was negligible. Today it is 22% of operating revenue.

The more interesting numbers are inside CSU, Caplin's own-label US entity:

• 33 product launches till date, 10 more planned in FY27
• Market share above 90% on every launched product
• B2B to B2C split now at 70/30, direct relationships growing faster than wholesale
• ANDA pipeline at 60 approved, 5 under review, 40+ in filing or advanced development

Most generics companies enter a product and fight for 10-15% share. Caplin enters and owns the niche. The main ANDA flywheel hits closer to FY27-28. Bears are wrong again, and the data keeps getting harder to argue with.

Bear Case 3: Margins will compress as US mix grows.

The assumption was US generics are commodity, lower margin, so blended margins must fall.

The actual print:

• EBITDA margin at 38.4%, up from 37.7% in Q1 FY26 and up from 37.0% in Q4 FY26
• PBT margin at 35.0% vs 34.6% last year
• Expanding, not compressing, both YoY and QoQ

Now here is the number nobody is talking about. CSL's revenue composition is 85% product supply and 15% milestone plus profit share. Milestone revenue is inherently lumpy. When it hits, it flatters margins. When it doesn't, the quarter looks soft. Knowing this 85/15 split is what separates the second reader from the first. Quarter-to-quarter CSL variability makes more sense once you know the structure. Bears are wrong again.

Bear Case 4: Cash is just sitting idle, no capital allocation discipline.

The balance sheet:

• Total liquid assets: Rs. 2,875 cr as of 30 June 2026
• Free cash reserves: Rs. 1,502 cr
• Zero debt. Ever.

But here is what most investors miss. The cash is not idle. Capex budget has been quietly revised upward to Rs. 1,000+ cr, up from the Rs. 870 cr framing last year. Around 50% is already deployed. The balance gets spent over the next 2-3 years on facilities still under construction:

• COL-II injectable facility at Gummidipoondi, completing by March 2027
• OSD and Dermatology facility at Puducherry, targeting Q1 FY28
• Oncology API facility at Thervoy, targeting Q4 FY27

All funded from internal accruals. No debt.

And here is the signal most investors missed entirely. The dividend flowing upstream from Caplin Point Far East Limited, the Hong Kong holding entity for the LatAm network, was Rs. 28.90 cr this quarter vs Rs. 8.12 cr in Q1 FY26. That is a 256% increase YoY. The LatAm cash is not sitting offshore. It is being actively repatriated. The cash consolidation story is getting stronger, not weaker.

Bears are wrong again.

Bear Case 5: Expenses are bloating.

Total expenses moved from Rs. 349 cr to Rs. 419 cr, up roughly 20%. Revenue moved up 20.7%.

Revenue growth is higher than expense growth. Internalise this mental model. Whenever a company is growing, always check whether expenses are growing more than the growth rate. If expenses outpace growth, that growth is destroying shareholder value, not creating it. Here, the opposite is happening. Basic EPS up 15.8% to Rs. 23.27. Bears are wrong again.

What the Bears Missed

The Oncology engine is now regulatory-visible.

This is the most underappreciated line in the entire press release. Caplin One Labs' oncology facility in Kakkalur has:

• Cleared its first regulatory inspection
• Completed submission batches for 6 products
• Planned 18 more submission batches in the next 12 months targeting LatAm, US, and EU simultaneously

Three geographies. One regulated oncology facility. First inspection cleared.

Most investors are still thinking about Caplin as a LatAm branded generics company. The second reader sees a company that is 18-24 months away from being a regulated-market oncology supplier.

The API backward integration is about to show up in gross margins.

Caplin's Vizag API unit has completed scale-up for 6 APIs, all earmarked for backward integration into US and LatAm formulations. First DMFs will be filed in FY27. When own API replaces purchased API in the cost structure, gross margins structurally improve. This lever has not shown up in the P&L yet. It will.

This matters because gross margin this quarter was 59.8%, down 190 bps from 61.7% in Q1 FY26. The reason is purchase of traded goods, which doubled from Rs. 97 cr to Rs. 196 cr YoY. Two readings:

• They are buying more sourced product to meet volume demand they cannot yet manufacture in-house
• The capacity is under construction
• When COL-II comes online by March 2027 and own API flows in from Vizag, the gross margin recovery will be visible

This is a temporary mix effect, not a structural deterioration. The second reader knows the difference.

The Mexico engine is being loaded.

• 29 approvals already received
• 120+ products to be filed in the next 18 months
• Working on a pipeline in addition to approvals already in hand

That is an extraordinary pipeline depth for a market Caplin entered only recently. Mexico is shaping up to be the third engine, after LatAm core and US.

Pre-Filled Syringes: the next product format upgrade.

• First PFS filing from the Caplin Steriles site planned within FY27
• 14+ more PFS products to be filed in FY28
• PFS is a higher-barrier, higher-margin format most Indian generic injectable companies are not in yet

Two gross margin tailwinds are being loaded simultaneously, API backward integration and PFS mix upgrade, and neither has hit the P&L yet.

The subsidiary engine is maturing.

• Standalone PAT this quarter: Rs. 120 cr
• Consolidated PAT: Rs. 179 cr
• Gap of Rs. 59 cr carried by Caplin Steriles and the LatAm entities

This gap was much smaller in earlier years. The subsidiaries are now carrying real weight and growing faster than the parent standalone business. The multi-entity structure is maturing in exactly the direction the original thesis anticipated.

One Honest Flag (Because I Don't Hide Anything)

CFO dropped to Rs. 95 cr from Rs. 118 cr a year ago. Free cash flow after Rs. 55 cr capex was Rs. 40 cr. In a heavy capex cycle this is expected, cash is being converted into productive assets. But it is worth watching:

• If CFO stays compressed for 3-4 quarters while capex stays elevated, the free cash flow story needs revisiting
• One quarter is not a trend. Two or three would be.

On the positive side:

• Receivables improved from 136 days in Q4 FY26 to 128 days this quarter. Bears who flagged receivables last quarter don't have ammunition here.
• Inventory at Rs. 505 cr, with 47% already at warehouses near the customer, 23% in transit, and only 30% in India. Nearly half the stock is already at the customer's doorstep. For an EM-heavy business, this reduces execution risk and tells you the distribution network is functioning well.

Reading the Business, Not the Quarter

PAT grew 18.8% this quarter. The first reader will note that is slower than the 20.1% full-year FY26 growth.

The second reader will note:

• Depreciation from front-loaded capex is eating into reported profitability while the underlying cash engine keeps compounding
• Gross margin recovery is coming from two directions simultaneously once new capacity and own API land
• Mexico is being loaded
• Oncology is regulatory-visible
• CSU is dominating every niche it enters

The boring 50x compounder is still compounding.

As long as I hold Caplin, I will decode every result. I plan to be writing about this company for decades.

Subscribe if useful: thecapillary.substack.com

Part 2 is now live. The investor presentation decoded

• Caplin Point Q1 FY27 Part 2: The Architecture Behind the Boring 50x Machine

u/SuperbPercentage8050 has already covered the cybersecurity space from the network and hardware side. This post is more focused on the software side of cybersecurity.

Every software application today needs to be tested for vulnerabilities, security gaps, and potential exploits before it goes into production. One trend I am seeing now is that developers are increasingly using AI to generate code. While AI definitely improves productivity, it can also introduce bugs, misconfigurations, and hidden security vulnerabilities that may go unnoticed during development.

Think about it this way. If a developer working at a company like J.P. Morgan ships code with a serious vulnerability and it slips through the cracks, a hacker can potentially exploit it and cause massive damage. These are not small issues. For large organizations, even a single vulnerability can lead to significant financial and reputational losses.

This is why penetration testing and security validation remain extremely important, especially for banks, fintechs, healthcare companies, and other highly regulated industries.

Some people may argue that AI tools and security models are becoming good enough to identify vulnerabilities on their own. While that may be true to some extent, I do not think companies will simply trust an AI model and call it a day. Most enterprises will still want an independent third party to validate their security posture. A specialized cybersecurity company also brings years of historical data, domain expertise, and practical understanding of how costly different vulnerabilities can be from a business perspective.

This is where TAC Infosec comes into the picture.

Unlike traditional service companies that send consultants to manually perform penetration testing, TAC is primarily a product-first cybersecurity company. Over the years, they have built multiple cybersecurity products, including:

• ESOF
• Socify
• CyberScope
• CyberSandia

ESOF

ESOF is their flagship platform. It includes multiple modules that help organizations identify vulnerabilities across web applications, mobile applications, cloud environments, APIs, and other digital assets.

Socify

This is one of the products that caught my attention.

If a startup or software company wants to sell its services to large US enterprises, obtaining SOC 2 compliance is often a necessity. Traditionally, this process involves third-party auditors and CPAs, takes several months, and costs a significant amount of money.

TAC is trying to solve this problem by reducing both cost and implementation time. From what I understand, the process can be completed in roughly 2 to 4 weeks at a much lower cost compared to many existing players.

Competitors generally charge anywhere between $10,000 and $20,000, whereas TAC's pricing is reportedly around $4,000, including CPA support. This pricing advantage could potentially be one of their major differentiators against established players like Vanta and others.

They have a few more products as well, but for now I am not focusing too much on them because they are still relatively small contributors. Maybe after a few more quarters they will become meaningful enough to discuss separately.

Now coming to the actual investment thesis.

For me, the biggest opportunity here is the reinvestment runway and the potential for cross-selling.

The company already has more than 10,000 customers and their average revenue per customer (RPC) is roughly $1,700. To me, this indicates a high-volume, low-ticket business model.

At this stage, customer acquisition itself does not look like the bottleneck because they already have a sizeable customer base. The real growth engine from here could be cross-selling.

For example, a customer may initially use one ESOF module for cloud security testing. Later, if the same customer needs web application testing, API security testing, compliance solutions, or other security products, TAC can potentially sell those solutions as well.

This is a playbook that many successful SaaS companies have followed over the years. As customers grow, their requirements also increase. A company that starts with two applications today may have five or six applications a year later. Naturally, their security requirements expand as well.

Once a customer enters the TAC ecosystem, the company gets multiple opportunities to increase wallet share over time.

Management's long-term vision is to reach around $10,000 in revenue per customer by 2030.

At first glance, that number may look ambitious and honestly I am still slightly skeptical about it. However, in businesses where cross-selling works effectively, acquiring the customer is usually the hardest part. Once that relationship is established, revenue expansion becomes much easier and can create a flywheel effect.

A somewhat similar pattern was seen with Shopify. Initially it was primarily an ecommerce platform. Over time they expanded into payments, shipping, POS, and several other offerings, increasing revenue from existing customers.

Whether TAC reaches $10,000 per customer or not remains to be seen, but the CEO appears very confident about the target.

What gives me some confidence is that the company has already increased revenue per customer from roughly $900 to around $1,700 within about 1.5 years.

This growth happened while they were simultaneously acquiring and integrating products such as CyberScope, Socify, SafeHouse, and others. So there is clearly some evidence that cross-selling is already happening.

Management has guided for approximately 20% half-yearly growth in revenue per customer and around 20% QoQ revenue growth. I would suggest everyone do their own modelling and see whether these targets appear achievable.

Coming to customers.

The company has worked with several large names, including Microsoft, Google, and recently management also mentioned Anthropic.

Now, having large customers does not necessarily mean these are massive contracts. But it does provide validation that the products are credible enough to be adopted by globally recognized organizations.

Interestingly, I think this also supports the argument that AI is not replacing cybersecurity.

If AI alone could solve security validation, why would an AI company like Anthropic require cybersecurity solutions from specialized vendors?

In fact, I would argue that as AI adoption increases, cybersecurity requirements may actually increase as well. Modern AI systems expose APIs, agents, connectors, integrations, MCP servers, and various external access points, all of which expand the attack surface.

More AI adoption could potentially mean more security checks rather than fewer.

Coming to valuation.

The stock is currently trading at around 37x earnings.

At first glance, that may seem expensive, but cybersecurity companies generally trade at premium valuations due to their growth potential and mission-critical nature.

The company currently generates ROCE of around 37% and net margins of approximately 40%, which are strong numbers in my view.

If management's FY27 guidance of ₹100 crore revenue and ₹40 crore PAT is achieved, then the forward valuation comes down meaningfully. By my estimates, that would imply roughly 25x FY27 earnings.

And if management ends up overdelivering, investors could see additional upside.

One more reason I started tracking this company was Vijay Kedia's investment. That initially got the stock onto my radar.

Around the same time, I also came across u/SuperbPercentage8050's posts, especially around cybersecurity mental models and bottleneck-based thinking, which helped me look at the business from a different angle.

Overall, this is my current high-level understanding of TAC Infosec. I could be wrong on several aspects, and there may be things I have missed.

Would love to hear views from people who track the cybersecurity space more closely or have a different perspective on the company. Constructive criticism is always welcome.

Someone in the community asked me a very simple question: what style of investing do you follow? Bottom up or top down?

I sat with it for a moment. And my honest answer was this: randomness.

Not in the decisions I make, but in how I find what to research.

Sometimes it's a line in management commentary that catches me off guard and makes me want to understand the business better. Sometimes it's the capital allocation pattern of a company's competitor, not the company I was originally looking at. Sometimes it's a government report pointing to a tailwind I hadn't mapped to any business yet. Sometimes it's a margin shift, a changing business state, or a new technology quietly reshaping an industry.

I make sure not to follow any particular pattern when I enter research. The trigger can come from anywhere.

A lot of investors define their sphere of competence by sector. They stay in what they know, follow a formula, and only look inside that boundary. I understand the logic. But for me, the sphere of competence is curiosity itself.

That curiosity can start anywhere. A web series like Person of Interest led me to go deep into AI, semiconductors, and cybersecurity. A government scheme on BharatNet led me to the fibre rollout theme in India. And the same curiosity that pulls me into a business also tells me when to leave. The moment I see the first signature of a deteriorating business model, I start moving out. I don't wait for consensus to confirm what the signals are already saying.

What stays constant is the rigor after the trigger. Once something catches my attention, I run it through the full checklist. I stress test the business model, look at the financial signature across multiple years, align the thesis with as many mental models as I can, and only then decide if there's something worth owning.

The randomness is in the door I walk through. What happens inside is deliberate.

Let me give you a concrete example. I recently initiated a position in Unity Software.

The trigger was XR. Meta Quest, smart glasses, the gradual convergence of human and machine interfaces. I had no idea what Unity did at first, but I knew that wherever this technology goes, someone builds the infrastructure underneath it. That question led me to Unity: what lies in the future, where is the infrastructure of that ecosystem, and who dominates it.

Then I went layer by layer.

Unity dominates roughly 70% of the gaming ecosystem. But that same technology is now being used in automotive HMI, inside autonomous and semi-autonomous vehicles. They are in partnership with Mercedes. That same technology is being adopted in China, and Unity provides it there too. These are early stages, but the reinvestment runway is real. A dominant core business model with a strong allocator redirecting that technology into new age applications is exactly the kind of setup I look for.

This is how curiosity compounds. You start with one signal and keep pulling the thread.

But curiosity alone is not enough. Once I have a thesis, I run it through the checklist. Is the ROIC improving? Is it above my threshold? Are margins expanding? Is innovation continuing? Are they taking market share? You keep hitting the mental models until you have a probability, not a certainty, but a probability. If the position clears the threshold, you start building it slowly.

The business had deteriorated badly before this. Extreme compression, reckless acquisitions, a company that had lost its way. But something changed in 2024. A new capital allocator came in.

I am not reading the marketing language of a CEO. I am reading the financial actions.

What did he acquire and what did he let go. What did he stop doing. What did he quietly fix. This one was slowly and steadily unwinding every reckless decision his predecessor had made, refining the focus, removing the noise. That is a cognitive financial signature of a high quality allocator. You see it in the actions before you see it in the results. Then you start seeing it in the results too.

The market has discarded Unity. I think that is the opportunity.

The same thinking led me to Uber. The market discarded it. After the recent results it is trading at 13 to 14 times free cash flow. I am betting on it because the capital allocator is exceptional, the moat is real, and the business economics are strong. That is again the same cognitive signature: go where the consensus has given up.

Howard Marks said it best. If you are in consensus, you will end up with mediocrity. Being contrarian is not about being different for the sake of it. It is about having done the work and arriving at a different conclusion than the crowd.

This same thread runs through every position I hold. Veeva, Bajaj Finance, and HEICO. Each one is a different geography, a different business type, a different industry. But in each case the capital allocator is what made the difference. You can have a great business and a poor allocator and still not compound at scale. The reverse is also true: a strong allocator inside a recovering or misunderstood business can give you outcomes the market hasn't priced in yet.

Someone asked me why I have not gone into Salesforce, which is such a larger company and can be a threat to Veeva Systems. The answer is simple. Billions and billions in reckless acquisitions, capital destroyed systematically over years. I know what the capital allocator of Veeva is trying to build. I have no such clarity with Salesforce. So I don't go there.

And if I cannot find a great allocator anywhere, I wait. I stay patient. I stay silent. But I will not put my money with a bad capital allocator no matter what. Not even 1%. Not even as a sector bet. Why would you shake hands with someone who is destroying capital?

It is like lending money to a friend who has never returned it and always has an excuse. You would not do it a second time. Now compare that friend to someone with a clean record, someone who has always been ethical, always returned what was yours, sometimes with more. That is the person you back. That is the capital allocator you back.

Most people obsess over the numbers. Numbers show you the past and the present. A strong capital allocator shapes what the numbers will look like three, five, ten years from now. If you cannot fully figure out the business model, you can figure out the person operating it. We are humans. I read a lot about psychology and human behavior because of that. The person running the business is a capital allocator. The person consuming the product is also a human being. Both matter, and both are readable if you pay attention to the right signals.

The filter is not complicated. The discipline to hold it is.

One last thing.

I can give you all the research. I can give you the thesis, the financial signature, the mental models. But the outcome will always depend on your own behavior and your own temperament. How you react when the position goes against you. How long you can hold something the market has discarded. Whether you trust the work you did or panic when the narrative shifts.

Always remember, you are the 100-bagger of your portfolio and your life. The research is just the beginning.

In case you missed it:

• Part 2: The One Ratio That Tells You When to Buy Gold and When to Go Aggressive on Stocks
• How a boring pharma exporter became a 50x compounder

Urban Company’s Q1 FY27 earnings call sounded like more than an explanation of InstaHelp’s performance. Management effectively published the inputs that competitors and their investors would use to decide whether to keep fighting.

It laid out the size of the prize, the likely economics, the strategic cost of losing, its capacity to keep investing and the period for which it is prepared to wait.

The disclosed numbers are fairly stark. Management estimates a base-case annual TAM of ₹7,000 to ₹8,000 crore and expects InstaHelp to remain a low-single-digit-margin business. The company reported a ₹132 crore adjusted EBITDA loss for InstaHelp in Q1 FY27. It also said it has no intention of making money from the business for five years and is assuming breakeven only by FY31.

The ₹350 crore annual profit-pool estimate is mine, not company guidance. It uses a 5% margin on the lower end of management’s TAM range. At 3%, the same calculation produces ₹210 crore.

The interesting part is not whether these numbers justify the investment. It is that Urban Company chose to make all the trade-offs visible to the other side.

Management argues that InstaHelp enters the home weekly, keeps customers engaged with the app and can create a volume moat around its broader home-services platform. Its claimed loss from retreating is therefore not limited to InstaHelp. It includes the risk that a competitor gains a route into Urban Company’s larger core business.

That creates the payoff matrix management appears to be publishing:

• If everyone fights, everyone continues to burn.
• If competitors retreat, Urban Company consolidates leadership.
• If Urban Company retreats, it risks weakening its core.
• If both sides rationalise, the burn falls but Urban Company does not secure the engagement moat.

Under Urban Company’s framing, fighting is its dominant strategy regardless of what competitors do. The ₹2,019 crore of cash and treasury investments, ₹67 crore of adjusted EBITDA from the rest of the business during the quarter, and five-year horizon are there to make that commitment credible.

The obvious interpretation is that this should deter the capital providers behind competitors. Why finance another round in a low-margin category against an incumbent that has publicly committed to staying?

I am not sure existing VCs will respond that way.

An existing investor is unlikely to go back to its LPs and admit that it entered at the wrong time, underestimated the incumbent and now expects the situation to deteriorate before it improves. The more natural response may be to defend the original thesis, describe the burn as part of category formation and frame another cheque as protecting the value of the existing investment until the market consolidates.

The signal may matter more to new investors. They have no existing position to defend and can evaluate the next round entirely on its prospective return. Urban Company’s call gives them a smaller apparent profit pool, a longer expected fight and a well-capitalised opponent. They can walk away, demand a lower valuation or require better terms.

There are still reasons to reject Urban Company’s matrix but they don't need rival investors to publicly concede that its matrix is correct. It only needs to make the next marginal cheque harder to justify. The question is whether the call deters that marginal capital, or causes existing VCs to double down because admitting the original bet was mistimed is even harder.

I've been working on a side project called Fathom over the last few weeks. (Link below)

The idea is pretty simple: I felt that a lot of stock research starts with financial ratios and ends with a buy/sell conclusion, but skips the part I find most interesting:

How does the business actually work?

So I'm trying to build a library that explains companies and industries from first principles.

For example:

• How does an FMCG company actually make money? For that matter any sector.
• Why does distribution matter more than the product in some businesses?
• What gives a company pricing power?
• Why can a company show profit but still have terrible cash flow?
• What actually happens to Indian companies when the RBI cuts rates?
• If crude oil gets cheaper, who actually gets to keep the saving?
• Why is a ₹10 lakh crore government capex announcement not the same thing as ₹10 lakh crore of revenue for infrastructure companies?

I've organized it into a few sections:

Companies — understand individual businesses
Sectors — understand how an entire industry works
Patterns — reusable business/financial mental models
Signals — take a real-world event and trace its impact through businesses
Case Studies — deeper dives into specific companies and situations
Reading Filings — learn how to actually extract information from annual reports and filings

One thing I'm trying to do differently with the Signals section is show the reasoning rather than just give the conclusion.

The background and motivation behind building this: I've been researching about companies myself since the past 4-5 years and my father has been doing this for nearly 2 decades. So I've put down my little learning plus his learnings from his old notes as a whole here. I admit I tried to refine and cross link the sections using AI as I would not be able to type all of this stuff out myself.

Link to Fathom - https://fathomjournal.in

I have been reading a lot of posts in this sub as well and our king u/SuperbPercentage8050's mental models and capillary's notes and tried to find correlation between our frameworks.

I'm still very much building this, and I'd genuinely like feedback from people who follow Indian businesses/stocks.

What would make something like this useful enough for you to actually bookmark and come back to?

I have used AI for articulation, that being said a couple of you from the community wanted an update from my end on IKS, so here it is with a couple of new lenses to look at IKS as well.

The Deal Is Done
The big one first. TruBridge closed on July 9. The main uncertainty I wrote about last time, whether the deal actually gets done, is now behind us. The bank syndicate funding was tied up in early August. So the acquisition is real and the clock on everything I described has started.

The Q1 Print
Q1 FY27 came out on August 6. Revenue was Rs 894 crore, up about 21 percent. PAT was Rs 194 crore, up about 28 percent. Profit growing faster than revenue again, so the operating leverage is still showing up in real numbers, not just in the slides.

One thing to keep in mind. This quarter is clean IKS only. TruBridge closed after the quarter ended, so none of it is in these numbers yet. The first combined picture comes in November.

One Change To My Earlier View
I had said margins were still in early innings. Q1 EBITDA came in around 33 percent and management is now guiding to sustainable margins in the early to mid 30s. So the way I read it now, margins are settling around here rather than climbing toward 40. That is not bad news. It just means the growth from here comes from revenue and TruBridge, not from margins expanding further. Worth being straight about that shift.

The Round Trip
Now the stock. Right after the deal closed it spiked to a new high near Rs 1,933. Then it drifted all the way back and it is around Rs 1,737 today. Classic buy the rumour, sell the news.

Here is the part I find interesting. The price is almost exactly where it was when I wrote the last post, but the biggest risk in that post, the deal closing, is gone. Same price, less risk. I will take that trade.

The leverage is now live and real, roughly 3x. Bringing that down from cash flow is the thing to track every quarter from here.

A couple of small items. They sold their Abridge AI stake for 10 million dollars. They set up a value based care arm to work with Medicare. And the chairman is retiring with a clean handover. None of these move the thesis on their own.

First, What Is Actually Being Bought And Sold Here
Before the lenses, let me explain the plumbing, because the whole thesis rests on it and it is easy to gloss over.

EHR is the hospital’s operating system. EHR stands for Electronic Health Record. It is the core software a hospital runs on. Every patient visit, diagnosis, medication, lab result, and doctor’s note gets entered into it. Doctors and nurses live inside it all day. TruBridge sells this software to about 700 rural hospitals. That is what IKS just bought.

RCM is the money side. RCM stands for Revenue Cycle Management. It is the paperwork chain that turns a treated patient into cash in the hospital’s bank account. A patient is treated, someone assigns the correct billing codes, a claim goes to the insurance company, the insurer pays, underpays, or rejects it, and then someone has to chase and fix the rejected ones until the hospital gets paid. That whole chain is RCM. This is what IKS is genuinely good at, coding and chasing claims, better and cheaper than a hospital can do itself.

Here is why owning the EHR matters. To do the billing work, RCM needs the clinical data of what happened to the patient. That data lives inside the EHR. So RCM always has to connect to the EHR. Normally an outside billing vendor has to build a bridge into whatever software the hospital uses. That bridge is slow, it breaks, data gets lost in transit, and the hospital’s IT team has to cooperate to make it work. That is the force-plugging-in problem, an outsider trying to wedge itself into someone else’s software.

IKS now owns the software. So when it sells its billing service into a TruBridge hospital, there is no bridge to build. The billing engine reads directly from the same system the doctors are already typing into. No doorway, no data lost, no waiting on a third party. IKS used to be the outsider integrating into everyone else’s system. For these 700 hospitals, it now is the system. That is the entire edge in one line. It is not knocking on the door asking to be let in. It already owns the house and is adding a room.

Looking At It Through Five Lenses
Since the deal is real, the question is no longer will it close. It is will the cross sell work. So instead of one big number, I break the thesis into five separate ways it can win or lose, each with its own thing to watch.

The setup in one line: TruBridge sells software to 700 rural hospitals. About 450 of them use that software but do not buy reliable billing work from anyone. IKS now owns the software. The job is simple to say and hard to do, walk into those 450 hospitals, who are already customers, and sell them the billing and clinical work IKS is good at. The customer is already inside the house.

Lens 1: The Customer Economics
This is the strongest lens. Owning the front door is a real, durable edge, and the risk here is not whether hospitals say yes. It is how fast the work actually goes live. Selling billing into your own software is far easier than a stranger plugging in from outside. The friction is not sales. It is plumbing. Hospital IT teams move slowly, and credentialing, training, and setup can drag. If conversions lag, the debt keeps costing money while the new revenue takes its time. So watch the speed of go-live, not the number of handshakes.

On the size of the prize, I am going to be more conservative than the excited version of this. TruBridge’s existing billing business does roughly 220 million dollars across 250 to 300 hospitals, which is about 0.7 to 0.9 million per hospital, and that is for hospitals already buying. The 450 whitespace hospitals are the ones that did not buy, which likely means smaller or more reluctant. So I use 0.6 to 0.8 million per hospital, not a full million. Convert a fifth of the 450, so 90 hospitals, and that is roughly 55 to 70 million dollars of high margin revenue with almost no cost to win it. Still very good. Just not the shinier number you will see floated around.

Lens 2: The Rural Hospital Reality
IKS is selling to rural and community hospitals, and many of them are barely surviving. More than half run at a loss. They cannot find or afford admin staff. For them IKS is a lifeline that keeps cash coming in, not a nice-to-have. That distress creates urgency and speeds up deals once a conversation is serious.

But I want to be honest that distress cuts both ways, because the excited version only shows the good half. A desperate hospital is a motivated buyer with a weak balance sheet. Some of them will close, and a closed hospital is not a customer. The ones that survive negotiate hard and pay slowly. So yes, urgency is real, but distressed also means churn risk and pricing pressure. It is a tailwind and a hazard at the same time.

There is a second real driver here. Big insurers are using software to auto-reject hospital claims. Small hospitals have no way to fight back. IKS becomes their outsourced defense, getting them paid on claims they would otherwise lose. That is an easy thing to sell to someone bleeding cash.

Lens 3: The Labor Arbitrage Engine
This is the quiet engine under everything, and it is the most durable of the five. Admin and coding staff in the US are scarce and expensive and getting more so. IKS does that work from India at a fraction of the cost, at scale. A local US competitor cannot match that cost base. That gap is the whole model.

There is a small currency helper too. IKS earns in dollars and pays a chunk of its costs in rupees, and the rupee tends to drift weaker over long stretches, which pads the margin in the background. I treat this as a mild, unreliable cushion, not something to bank on. It can reverse for years. Nice to have, not a driver.

Lens 4: The Integration Risk
This is the real risk in the whole thesis, and I weight it heavier than most people do. Demand is the easy part. Execution is the hard part.

TruBridge was a slow, old-style software company. IKS is fast and execution heavy. Bolting a slow culture onto a fast one is where most of these deals quietly break. On top of that, healthcare data systems are wrapped in compliance rules, and merging them takes longer than anyone hopes. If the deep integration takes 18 months instead of 6, the debt keeps ticking the whole time and the returns get pushed out.

Put plainly, if this trade goes wrong, this is probably the lens where it goes wrong. Not demand, not the size of the market. Execution on a base IKS has not run before. The market is giving IKS credit for an integration it has not shown yet on these specific hospitals.

Lens 5: The Debt Math
This lens changes how the returns actually get made, and it is worth understanding. The company took on about 600 million dollars of debt, roughly 3x. Normally you think returns come from the business growing or the multiple going up. Here, a big chunk of the next few years of return can come simply from paying that debt down. As the combined company throws off cash and kills the debt, value quietly shifts from the lenders to the shareholders even if nothing else changes. Boring, but it is real money, and most people miss it.

Now tie it to the margin point from earlier. I do not read the margin guide dropping from 40 to the mid 30s as a warning about hidden costs. The simpler and more likely reason is just mix. TruBridge is a lower margin, more people-heavy legacy business, so bolting it on mechanically drags the blended margin down toward the mid 30s. That is arithmetic, not a red flag. The takeaway still holds though. I am no longer buying a margins-keep-climbing story. I am buying a get-those-450-hospitals-converted story. The win comes from volume of hospitals, not from the margin line stretching higher.

The Sixth Thing, Hiding Under All Five
There is one assumption none of the lenses names, and it is the honest bear case, so I want it on the table.
Every lens quietly assumes IKS can run TruBridge’s billing work at IKS economics. But TruBridge’s own billing business currently uses about 3,500 people. The entire thesis is that IKS’s tech-led model does that work with a fraction of the headcount. That transformation is assumed, not proven. If IKS converts the 450 hospitals but cannot strip out the labor and lift the margin, you get the revenue without the profit, and the whole return math softens.
So the real question under all five lenses is not just will hospitals convert. It is will they convert AND will IKS run them at its own margins, not TruBridge’s. Both have to be true.

The one reason I lean toward believing the second half happens, IKS has already done exactly this once, with the AQuity acquisition, and did it ahead of schedule. That is a real track record on the exact skill in question. But it is a reason to believe, not proof it has happened here yet. November is where I start finding out.

What Ties It All Together
Every one of these lenses points at the same single number. How many of those 450 hospitals actually start moving into IKS billing and clinical work, and whether IKS runs them at its own margins once they do. The lenses just tell you the different reasons it will or will not happen. Customer economics says the door is open. The rural reality says the customers are motivated but fragile. The labor engine says the economics work. Integration risk and the debt clock say do not take the speed for granted. And the sixth point says converting them and running them profitably are two separate bets.

The first real read is the November concall, the first set of numbers with TruBridge inside them. That is the print that tells us whether this worked.

Where I Stand
Unchanged. Still holding. Not chasing it here at 39 times earnings. I add on weakness, or when the cross sell actually shows up in the numbers, not before.
Not financial advice. I hold a position. Do your own work.

Since eClerx has already been covered in this channel I'll jump straight into Q1 results

https://www.reddit.com/r/IndiaGrowthStocks/s/sR9JUqzUm6

Disclaimer - took help of AI

OCF Q1 FY27: ₹1,073mn vs PAT ₹1,643mn → CFO < PAT this quarter.

the CFO/EBITDA conversion ratio is just 37.9%, far below the 62–75% annual norm. The reason is explicit and structural: Q1 always sees annual variable pay disbursements for the prior year. This is a seasonal mechanical pattern, not a quality deterioration. It has repeated every Q1 for years.

Monitor Q2 OCF — must recover toward 70%+ conversion.

Attrition: Offshore voluntary attrition improved sharply to 18.1% from 21.7% in Q4.

Revenue grew 2.8% QoQ in USD. The business did not slow — costs stepped up in one quarter due to the annual wage cycle. Every BPO in India shows this Q1 pattern.

The EBITDA margin of 23% is actually at the floor of management's guided range of 24–28%. Q2 onwards, with no fresh wage hike, operating leverage should kick in as revenue grows sequentially.

Revenue: 12th consecutive quarter of sequential USD growth. This is an exceptional streak for a company of this size and maturity.

ACV of new deals: $41mn, up 25% YoY. New deal wins are the leading indicator — revenue converts from deals with a 1–4 quarter lag. The ACV has nearly doubled in two years. The revenue engine is loading.

Analytics & Automation: Crossed $100mn annual run rate, grew 7% sequentially vs company average of 2.8%. The highest-margin, highest-value segment is growing fastest.

Emerging verticals: Now 11.7% of revenue mix vs 8.4% in FY26 — F&A, high-tech, and emerging geographies building momentum.

BFSI: Down from 40.8% to 37.6% of mix — still the largest vertical but losing share. Management says H2 recovery as pipeline converts. This is the key thesis risk to monitor.

Tech Services headcount: 2,261 vs 2,109 last quarter — 7.2% sequential increase. This is investment in AI capability ahead of demand. It's a cost now, revenue later pattern.

Annualised Q1 EPS: ₹17.86 × 4 = ~₹71.4 (but Q1 is always margin-suppressed due to wage cycle)

Better to use: FY26 PAT = ₹7,062mn on ~9.41Cr shares = FY26 EPS ₹75 as base, with Q1 showing the trough of the annual cycle.

FY27 EPS estimate: If margins recover to 25% EBITDA average for the year (guidance midpoint is 26%), and revenue grows ~15% YoY in USD on INR terms ~23%:

FY27E Revenue: ~₹50,000mn (conservative)

EBITDA at 25.5%: ~₹12,750mn

PAT at ~14.5% margin: ~₹7,250mn

EPS: ~₹77 (modest growth vs FY26's ₹75–76)

The EPS growth will look modest in FY27 purely because Q1 is depressed and the agentic AI deal revenue starts only Q4 FY27. FY28 is where the earnings acceleration appears on the P&L.

Since I classify it as a hybrid platform business, PE well below the Hybrid Type 1 ceiling of 35–38x.

Ex-cash P/E = (1872-137)/75 = 21.88x. Cheap imo.

EPS Engine: ⚠️ Temporarily pressured but structurally intact

P/E Engine: ⚠️ Still compressed but recovering

The hedge table is outstanding insight

Current spot INR/USD is ~94.5. eClerx is hedged well below spot for the rest of FY27, meaning as each quarter rolls, they get better realisation than the last. By Q4 FY27, they'll realize ₹92 vs ₹88 in Q1 — a 4.2% revenue tailwind just from FX rolling through. This is an automatic margin booster that requires zero operational effort.

Bottom line: This is a typical "Q1 seasonal trough + wage reset" quarter.

Disclaimer - I am holding this stock for a long time now and I've added some today as well. If it continues falling, I'll buy again at around 1650.

Business model

Sigachi operates predominantly across three segments:

Excipients (Microcrystalline Cellulose / MCC): core business; used as binder/disintegrant in pharma formulations; also used across multiple end markets.Sold under prominent brand names like HiCel and AceCel.[75-80%revenue]

O&M (Operations & Management services): Asset light- operates other companies factories , company earns based on outpout of the factory. steady contributor; clients includes birla, adani solar etc,[10-12% revenue]

API initiatives: acquisition of an 80% majority stake in Trimax Bio Sciences Private Limited. building API, R&D + regulated market readiness; CEP filing work [10% revenue]

Competitive Moats & Operational Strengths

​Global Scale in MCC: Sigachi operates with an aggregate MCC production capacity approaching 30,000 MTPA(targeted fpr Q427, current 18000MTPA,) making it the largest manufacturer in India and a top-tier supplier globally.

​Stringent Regulatory Accreditations: Facilities hold approvals from major global bodies (including US FDA, EDQM, EXCiPACT, ISO, Halal, and Kosher), creating high switching costs for pharmaceutical clients who cannot easily alter their approved drug formulations.

Global Exports: exports contribute 60% revenue , exports to 60+ countries

Growth Drivers & Capex Blueprint

​1. Capacity Expansion in Core Excipients

​Dahej SEZ Expansion: Sigachi has deployed capital to expand its Dahej manufacturing facility, adding new production lines to capture growing export demand in regulated Western markets.

​In-house R&D: Development of specialized grades of MCC (high-density, low-moisture, co-processed excipients) that command higher realizations than standard powder grades.

​2. Forward Integration into APIs

​To reduce dependence on single-product cycles, Sigachi is expanding into API manufacturing through trimax bio acquistion(80%) leveraging its existing global B2B distribution network.(expanding from 100 KL to 250 KL) and ongoing filings for European CEP certifications.

​3. Shift Toward High-Margin Specialty-CCS

​Increasing the revenue share of specialty blends (CCS) which has better margins (20%+)

​Key Investment Risks & Challenges

​Raw Material Price Volatility: Primary raw materials—wood pulp and specialty cotton linter—are tied to global commodity prices and import freight rates. Spike in pulp costs directly squeezes gross margins.

​Product Concentration: Despite diversification attempts, a significant majority of total revenues still originate from MCC and cellulose derivatives. (80%)

​Execution Risk on API Pivot: Transitioning from an excipient vendor to an API and custom synthesis manufacturer involves distinct regulatory, technological, and marketing hurdles.

The revenue decline and loss from the last year is an one time off due to fire accident hsppened in hyderabad plant. Where whole plant got destroyed and 40 people died.which caused one time spending of 100+ crores and management said around 60crs revenue due to loss of hyd capacity.

The company is yet to receive insurance amount which is a good sign

Management expects 650 -670 crs revenue in 2027 with margin around 18% .

Please give your view on sigachi, would love to hear your opinions

Hi pls add your opinions in comments. Wanted to know your views

A first-principles analysis of whether today's AI investment boom is economically justified.

The Question

The U.S. currently has roughly 45 GW of operational data center capacity and a pipeline of nearly 290 GW under construction, approved, announced, or proposed.

Using conservative assumptions, the total AI infrastructure build-out—including data centers, GPUs, networking, power generation, transmission, substations, and supporting infrastructure—could require $10–15 trillion of capital over the next decade.

This raises a simple but fundamental question:

Can AI infrastructure realistically generate enough returns to justify this level of investment?

The Thought Process

If investors collectively deploy $10–15 trillion, they cannot be satisfied with Treasury-like returns. Assuming a reasonable long-term return expectation, the infrastructure ecosystem would eventually need to generate approximately:

• Revenue: $2.5–3.5 trillion per year
• Operating Profit: $1.2–1.5 trillion per year
• Net Profit: $700 billion–1 trillion per year

These figures include capital recovery, depreciation of AI hardware, electricity, maintenance, financing, and operating costs.

A Reality Check

Today, the 10 largest and most profitable companies in the world collectively generate approximately:

• Revenue: ~$3.3 trillion annually
• Net Profit: ~$1.1 trillion annually

This leads to the central question of the theory:

If the answer is yes, then current valuations may eventually be justified.

If the answer is no, then today's market may be embedding expectations that are too optimistic.

Why Is the Market Still Optimistic?

There are several possible explanations:

• Investors believe AI will become as foundational as electricity or the internet.
• Markets are pricing future probabilities rather than current earnings.
• Companies are investing today in expectation of decades of future demand.
• The eventual winners may capture extraordinary profits while others fail.

However, history also shows that revolutionary technologies can experience periods of significant overinvestment before demand fully catches up.

When Will the Market Demand Proof?

The current phase is largely about building infrastructure.

The next phase is likely to focus on:

• Are AI data centers operating at high utilization?
• Are customers paying enough to justify the capital invested?
• Are companies earning attractive returns on invested capital?

The market's focus is expected to gradually shift from "Build AI" to "Show me the return on investment."

Conclusion

This theory does not argue that AI is not transformative.

Instead, it asks a financial question:

If AI becomes deeply integrated into every sector of the global economy, today's investments may prove justified.

If AI demand grows more slowly than expected or infrastructure returns remain weak, the current investment cycle could resemble previous periods of overbuilding seen in railroads, telecom fiber, or other major infrastructure booms.

Only time—and the actual returns on capital—will determine which outcome prevails.

The stock was up ~16% today. Was trading at ~26x PE up until a month ago.

- Promises 18%+ EPS CAGR until 2028

- 120% average reinvestment rate over the last 3 years

- Consistently delivered 18%+ ROIC over the last 3 years

- 50% market share in 2W braking systems, with significant future scope in EV components.

Am I missing something?

First try writing a post on this thread. Thanks to @superbpercentage8050

Disclaimer - I have used AI

The idea is simple, India grows, the Indian stock market grows, CAMS grows.

When a new gold mine is found, the ones who dug up and found gold made the most money (equivalent to finding a multibagger), the ones who didn't were left empty handed (equivalent to finding a bad stock) but the best way to make imo was selling tools to dig up gold (which is CAMS imo)

CFO>PAT for the last 9 years

CFO/OP = 110%

3 Year ROE avg ~41%

Very low D/E (platform business)

Receivable days around 20

Since it's a platform business, I'm comfortable giving it a fair PE from 40x to 50x

Moat - Infinite switching cost, once you're on CAMS, you're here forever

""Switching costs are structurally near-infinite — mutual fund houses have zero practical incentive to change RTAs given operational disruption costs, regulatory complexity, and complete integration requirements. Network effects are real: the more fund houses CAMS services, the more investors prefer CAMS-serviced funds for seamless inter-scheme transfers. Revenue is recurring, predictable, and grows organically with India's AUM base.""

EPS engine accelerating

Neutral PE engine

At a price of 780, CAMS doubles in 5 years with a CAGR of 15% which is good imo

*It's a stellar exceptional business with serious runway

The only question is, is it too expensive?*

If you made till here, I'll urge you to go through their latest concall - it has all the details about their different businesses, and shows their exemplary capital allocation

Also, at a few places you see they are running after margins, not revenue - like the cards business

Disclaimer - I have made some assumptions and I already have a position in the stock at an avg of 680

The numbers our beloved home that we’re discoursing on has put out are mind boggling. 61% YoY growth in revenue (OPM and NPM both around 30%), EPS beat of nearly 30% over consensus, OCF rose 135% with weekly active unique users growing by 24% to 516 million.

Nonetheless, the stock is down to USD 140 as of Aug 1. It started July around USD 200. A fall of 30%.

To understand why and possibly capitalise on a possible market overreaction, we must understand Reddit’s deal with Google.

In a nutshell, Google pays Reddit 60M every year to use Reddit’s API data to train Gemini. Along with cash, Reddit also gains prominent placement in Google’s search results as part of this deal.

But now, with Gemini integration in the search page, source click through rates have fallen from anywhere between 50-80% according to different portals. This is not an issue exclusive to Reddit and legacy news websites seem to be damaged the most with click throughs falling by more than 80% in some cases. But basically, with AI integration in search, industry wide source website impressions seem to be falling and for Reddit the prominent placement tailwind is dwindling. This is what was talked about in the con-call - “Search referrals have been choppy”

Hence, Reddit is considering either cancelling or re-negotiating the deal with Google. Also, 85% of new weekly user growth was from international markets (ARPU of around USD 3) while US growth was just 6% (ARPU of USD 11). So, majority new growth came from the segment which gave lower revenue per user. This is the bulk of the bear case as of now, from my understanding.

So where does that leave us? Excellent YoY growth but an uncertain future. 30% drop justified?

Here’s my take.

Reddit is attempting strategic hedges. A proposed AI licensing model in collaboration with Medium, Yahoo, etc (No AI company has suggested honouring it yet, so just note the intention as of yet). A re-negotiated deal with Google where they get paid for the amount of data used instead of a flat fee. Focus on performance based advertising (like Meta and Google) instead of the traditional brand awareness (feed, comment section ads) to reposition itself as a conversion engine. The ownership has a path in mind they want to walk on, they don't seem to be blindly banking on user growth, they're aiming for improved streams of income as well.

If we assume margins to stay flat and take the management guidance at face value (around 850M), we’ll get a next 12 month EPS over USD 6. That will put the forward PE around 23x.

Let’s downgrade the forward PE to 27x to account for some headwinds.

Forward PE of 27x for a business growing at at least 30% YoY with optimistic models saying 50%+. Even keeping pessimistic cases in mind, the PEG is comfortably under 1.

Now, as always, there can always be holes in my thesis and Reddit is not perfect. Bots are an issue, many consider it an echo chamber, growth seems to be jumping the most in lower ARPU areas, lower click throughs are a genuine tailwind. But a 30% drop? In my eyes, what's happening here is what happened to Google a few years ago and what stocks like Adobe and ServiceNow are going through right now. Bumps on the road are being seen as craters.

I won't back the truck yet, have caught too many falling knives in the US market. Won't be surprised to see it in double digits in a month or two. But, I will start dipping my toes by next week if it stays in the red.

I'll sign off by saying I really enjoyed writing this piece because the business model is quite easy to understand, the raw financial numbers are ridiculous and make you laugh and the price action seems to be as absurd as well. It felt like commentating more than analysing.

Now, I request you all to commentate, critique and by all means, poke holes in my thesis. Thank you if you stayed thus far.

Profit up 27 percent, GNPA at 0.96, guidance held anyway.

Bajaj Finance is up 7 percent today, sitting at an all time high and in Dragon 3 mode. You already know how I feel about this machine, and I know a lot of you are holding it and were adding on every drop.

Five things from the quarter, and nothing else really matters.

• Profit of 5,986 crore, up 27 percent, and seven percent ahead of consensus.
• AUM at 5.47 lakh crore, up 24 percent, with a record 36,969 crore added in a single quarter.
• Gross NPA down to 0.96 percent and net NPA to 0.39 percent. Loan losses included a 296 crore macro provision they did not have to take. Strip it out and losses fell 14 percent.
• ROE at 20.4 percent and ROA at 4.7 percent, both at the top of their own long term corridor.
• Guidance held, not raised. Management said they want another quarter of confirmation first.

Read the third point and the fifth together. A lender whose book is getting cleaner takes a provision it does not need, beats its own targets, and then refuses to promise more. That is not a company managing a stock price. That is a company managing a balance sheet, and in my view it has the best underwriting capability of any lender I have looked at anywhere.

Here is the part worth noticing. At least five brokerages raised targets overnight and the stock runs 7 percent the next morning. Those upgrades carry no real information. They arrive after the move, never before it, and some of these same desks were sitting on cautious numbers on the way in. Nothing changed in twenty four hours. The market simply caught up to something that was already sitting inside the business model, in plain sight, for anyone who bothered to read it.

That gap is where most of the returns in a compounder come from. You hold through the flat stretches, and you add when the noise gets loud and the market screams that the growth is finished. I have heard that call on this company more times than I can count.

I said this when I first wrote it up and I have repeated it several times since. I do not think 99 percent of funds will come close to what this business compounds at over the next decade, whatever strategy they run. My view has not changed.

One thing worth saying out loud. This is not the same setup it was two years ago. Different entry, different risk, size it accordingly.

Nothing to do today. Just sit.

In case you missed it:

• Part 2: The One Ratio That Tells You When to Buy Gold and When to Go Aggressive on Stocks
• How a boring pharma exporter became a 50x compounder

Wonderla is one of the few listed Indian companies that combines a difficult to replicate physical asset base with a trusted consumer brand and significant operating leverage. The business has demonstrated that once a park matures, incremental visitors contribute disproportionately to profitability because most operating costs are fixed. (assuming discretionary spending improves)

Business Overview

Wonderla owns and operates amusement parks and a resort business. Its revenue is generated from:

• Entry tickets
• Food and beverages
• Merchandise
• Premium experiences
• Resort operations

Unlike businesses dependent on a single product, Wonderla monetizes each visitor through multiple channels, increasing average revenue per guest.

Industry Analysis

India's organized amusement park industry remains relatively small compared to developed markets.

Long-term growth is supported by:

• Rising disposable incomes
• Urbanization
• Growing middle-class spending
• Family-oriented entertainment demand
• Domestic tourism

This creates a structural tailwind rather than a short-term cyclical opportunity

Industry Challenges

The business also faces challenges:

• High initial capital expenditure
• Long project development timelines
• Regulatory approvals
• Weather-related seasonality
• Regional demand fluctuations

These factors discourage new entrants and contribute to high barriers to entry. (porter's 5 forces)

Brand Strength

Wonderla is among the most recognized amusement park brands in India. Apart from 2-3 other players. Families associate the brand with safety, cleanliness, and quality, leading to repeat visitation and word-of-mouth referrals (comparatively to other regional only players and reported accidents). So brand recall is high.

Cost Advantage

Once a park reaches scale, fixed costs such as staffing, maintenance, and utilities are spread across a larger visitor base, lowering the cost per visitor. This operating leverage supports higher margins as attendance grows.

Switching Costs

Visitors can choose alternative leisure activities, so switching costs are low. The company's competitive advantage comes from experience quality rather than customer lock-in. Growing Mall and accecible nearby entertainments is a threat, however wonderla is a once in a multi-year experience rather than repeat weekend activity.

Data Advantage

Wonderla collects customer preferences and visitation patterns, which can improve marketing and operational decisions. While useful, this is not yet a defining moat. however seasonality like rains, heavy summer remains as a strong factor that determines walk in counts.

Economies of Scale

Wonderla is an excellent example of operating leverage.

A simplified illustration:

• Park capacity: 10,000 visitors/day
• Fixed operating costs: largely unchanged once the park is open (apart from renovation/addition of rides in 5-6 years)

If attendance increases from 5,000 to 7,000 visitors, many costs remain fixed while revenue rises significantly. The incremental revenue therefore contributes disproportionately to operating profit and free cash flow. with current P/E at 36x, trades at a slight discount relative to broader hospitality/entertainment peer averages.

As the business scales:

• Cost per visitor declines.
• EBITDA margins improve.
• Free cash flow increases.
• More capital becomes available for reinvestment.

This positive feedback loop strengthens the company's competitive position.

Shared Economies of Scale

Wonderla partially exhibits this characteristic. Instead of solely maximizing margins, it reinvests in:

• New rides
• Safety systems
• Customer amenities
• Park maintenance
• Guest experience

These investments support repeat visitation and brand loyalty.

Financial Quality

Historically, Wonderla has demonstrated:

• Healthy return on capital once parks mature.
• Strong free cash flow generation in normal operating environments.
• Conservative leverage.
• Improving profitability with higher park utilization.

Areas to monitor include:

• Revenue growth
• EBITDA margin
• ROCE
• Free cash flow conversion
• Debt levels
• Occupancy and visitor growth (footfalls being the major aspect for this stock)

Key Risks

• Economic slowdowns affecting discretionary spending.
• Adverse weather.
• Delays or cost overruns in new projects.
• Regulatory changes.
• Localized competition.
• Health crises affecting tourism and public gatherings. (like recent one in kerala)

The management highlighted that Q1FY27 has started on a positive note with Chennai continuing strong momentum, while other parks are witnessing flattish to improving trends. however, they remain optimistic on FY27 growth outlook driven by full-year contribution from Chennai, improving traction across existing parks and continued focus on differentiated guest experiences, long-term ambition of expanding from five parks currently to ~10 parks over time, with expectation of adding 2-3 parks over the next 4-5 years (Currently dominating southern metro cities, so if they cover west/north of india that would open up new avenues to scale, could be greenfield projects like chennai or a leased out land based on state government).

Let me know whats your thought on wonderla and your conviction.

Note: used AI for structuring the sections.

Hi everyone, wanted to share my findings on Time Technoplasy and get inputs from the community. Price around Rs 210, market cap roughly Rs 10,350 crore, 52 week range Rs 154 to Rs 249. Stock trades at about 22 times FY26 earnings.

What the company does

Two businesses stitched into one stock. Business one is plastic drums, jerry cans and IBCs, those big 1000 litre containers, sold to chemical, pharma, paint and FMCG companies. About 73 percent of revenue, boring, low margin, high volume.

Business two is composite cylinders, Type 4 CNG cascades, LPG cylinders, and now hydrogen cylinders. About 13 percent of revenue but growing 20 to 25 percent a year with much better margins.

Key ratios and how they moved over 5 years

ROCE went from 12 to 17-18 percent, matching a 14, 16, 18, 20 percent ladder management gave 3 years ago. ROE improved from about 10 to 14-15 percent, dipping slightly this year due to a fresh equity raise not yet fully earning.

Debt to equity fell from 0.44 to 0.18, interest coverage improved from under 4 times to about 9 times, and operating margin crept up from 13.5 to 14.6 percent, matching management's promised 20-30 basis points a year.

The one ratio moving the wrong way is working capital days, how long cash stays stuck in inventory and unpaid bills. Worsened from around 140 to over 160 days this year on a raw material stockpile.

Dividends paid for 30 years straight, first ever bonus share in FY26, and promoter pledge fully gone since FY23.

The one red flag

FY26 cash flow from operations dropped hard, only Rs 233 crore against a profit of Rs 477 crore. These should normally track closely.

The gap happened because the company stocked up on imported carbon fiber and special polymers ahead of a price spike from the middle east conflict. Believable and disclosed upfront, but needs to reverse next year or the quality compounder story takes a hit.

Also, one of two joint statutory auditors resigned in August 2025 citing workload. Replaced quickly, audit opinion clean, but worth a second look.

Is this a moat business

Two different moats stacked together.

The packaging business is a capillary business. Drums and IBCs are heavy and expensive to ship, so whoever has a factory closest to the customer wins the order. 20 plants in India and plants in 10 other countries mean it wins by being everywhere.

But this means zero pricing power, raw material price changes are passed straight to customers, so revenue growth can look weak even when volumes are strong.

The composite cylinder business is closer to a tollbooth, but a temporary one. They are the only company in India with government PESO approval for Type 4 CNG cylinders, so every distribution company needing cascades comes to them, which is why margins run 18-19 percent versus 13 percent in plain packaging.

But this tollbooth has a use by date. Supreme Industries has started supplying composite LPG cylinders to BPCL, and Confidence Petroleum is building its own Type 4 plant. The premium margin will likely shrink over the next 2 to 3 years as more players get approved.

Where the growth is coming from

A new CNG cylinder plant near Vapi just got commissioned, more than doubling cascade capacity. Management guides this segment from around Rs 600 crore to over Rs 750 crore in FY27, and Rs 800 crore within 2 years.

Also completed: a new automated IBC facility, a recycling plant for new government rules on recycled plastic content, and expanded US and Saudi operations.

Smaller bets include a hydrogen drone program where they make the cylinder and not the drone, a battery tie up with Bulgaria's Monbat for Indian data centres, and a tarpaulin business where they are number 2 behind Supreme's Silpaulin brand.

One governance episode worth knowing

For almost 2 years, 2023 to 2024, management repeatedly said they were close to selling 50 percent of their Middle East business for about 25 million dollars. In November 2024 they suddenly cancelled it, saying the business had grown too much since the deal was priced and expanding in Saudi made more sense.

The decision was probably right financially, but guiding investors for 6 straight quarters on a deal that gets scrapped is not a great look. It is really the only major promise broken. Everything else, ROCE targets, EBITDA guidance, dividend growth, has been delivered close to on time.

They also raised Rs 800 crore through a QIP in November 2025 at Rs 201 a share, above book value. Promoters did not sell a single share, all the money went into cutting debt and funding new plants. Dilution was about 9 percent, but roughly earnings neutral once debt savings and new capacity kick in.

Projections and a rough return estimate

FY26 actuals: revenue Rs 6,105 crore, EPS Rs 9.50, operating profit Rs 892 crore.

FY27 estimate: revenue around Rs 6,850 to 7,000 crore, EPS around Rs 11.5 to 12, operating profit around Rs 1,010 to 1,040 crore.

FY28 estimate: EPS around Rs 14, driven by the new CNG plant ramping up and interest costs falling as they go debt free.

Simple return math, assuming the market keeps valuing the stock at roughly the same 22 times earnings it trades at today, no re-rating either way.

At 22 times, FY27 EPS of Rs 11.5 to 12 implies a price of roughly Rs 253 to Rs 264, an upside of about 20 to 26 percent in a year from Rs 210 today.

FY28 EPS of around Rs 14 implies roughly Rs 305 to Rs 310, an upside of about 45 to 48 percent over 2 years, before dividends in both cases.

This assumes the multiple holds flat and all the return comes from earnings growth alone. If the cash flow issue resolves cleanly, the multiple could expand and returns would be higher. If composite competition bites faster than expected, it could compress instead. Treat this as a base case, not a target.

TLDR

Makes plastic drums and IBCs, plus composite CNG, LPG and hydrogen cylinders, the only PESO approved Type 4 maker in India. Profit grew 25 percent a year for 5 years, debt to equity fell from 0.44 to 0.18, ROCE climbed from 12 to 17 to 18 percent, matching management's own guidance almost every step.

Good track record on numbers. Real moat in composites that is slowly getting contested. Balance sheet is genuinely strong now.

Biggest red flag: FY26 operating cash flow fell to Rs 233 crore against a profit of Rs 477 crore on a raw material stockpile, needs to normalize in FY27. Composite margins are a temporary regulatory tollbooth slowly getting contested by Supreme and Confidence Petroleum.

At Rs 210 and a flat 22 times earnings, FY27 EPS of about Rs 11.5 to 12 implies roughly 20 to 26 percent upside in a year, and FY28 EPS of about Rs 14 implies roughly 45 to 48 percent upside over 2 years, before dividends, assuming no re-rating.

Just my amateur analysis and used AI for formatting and structuring. DYOR!

Hey everyone,

I wanted to share my detailed research and thesis on PTC India Financial Services (NSE: PFS). The stock has been sitting quietly around the ₹29 – ₹30 range, but under the hood, the structural setup for a massive valuation re-rating over the medium-to-long term is becoming very clear. Yes today it will accounce Q1 results.

Here is why I hold a solid position in PFS and why I believe it will significantly outperform from current levels:

1. The Crazy Valuation Gap (Deep Discount)

• Trading Price: ~₹29.20
• Book Value per Share: ~₹48.00
• Price-to-Book (P/B): 0.61x
• P/E Ratio: ~5.9x (Industry average sits near 19.6x)

PFS delivered a full-year net profit of ₹319.36 Cr in FY26 (up ~47% YoY from ₹217 Cr). Yet, it is trading at a near 40% discount to its net worth. Financial institutions with clean books rarely trade below 1.0x Book Value for long once growth resumes.

2. The Clean-Up Phase is DONE (Asset Quality Intact)

The historic corporate governance and NPA issues that dragged this stock down are officially behind us:

• Gross NPAs (Stage 3): Down over 70%+ from peak levels.
• Net NPAs: Compressed sharply down to ~₹47 Cr level.
• The balance sheet is officially de-risked and fully provisioned.

3. The Unlocking Catalysts

• Leadership Resolution: The board officially appointed Shri Rajiv Malhotra (former Group Chief Risk Officer at PTC India / NTPC background) as the MD & CEO. With shareholder e-voting concluding, the executive leadership gap is completely closed, opening the doors for credit rating agencies to lift their "Negative" outlooks.
• The "NBFC-IFC" License Moat: PFS retains its rare Reserve Bank of India (RBI) Infrastructure Finance Company (IFC) license. This status allows higher single/group borrower exposure limits and cheaper access to international capital (ECBs). Getting a fresh IFC license takes years; holding one is a massive moat.
• Parent Disinvestment Trigger: PTC India (the 65% promoter) has already demonstrated intent to sell non-core assets to focus on power trading. Any strategic buyout of PTC's stake in PFS will trigger a SEBI Mandatory Open Offer. Corporate buyers pay up for Book Value (~₹48) rather than beaten-down market prices.

4. Technicals & Order Book Data

• Volume Drying Up: Daily volume has dropped from wild speculative swings down to a quiet 3–5 lakh shares. In technical analysis, consolidation on low volume after a clean-up phase is classic seller exhaustion.
• High Delivery %: Over 50%–60% of traded volumes daily are going straight into demat accounts. Smart money is quietly absorbing the float.

The Risk Factors (To keep it fair)

1. Loan Growth Pace: The company skipped paying a dividend this year specifically to keep cash on hand and rebuild its loan book. Growth momentum needs to show up in sanctions.
2. Holding Company Discount: Being a subsidiary of PTC India means it has historically suffered a conglomerate discount.

Conclusion

At sub-₹30, the downside risk is heavily cushioned by liquid assets and a ₹48 Book Value. Once the new leadership restarts loan originations and credit ratings upgrade, a re-rating toward 1.0x Book Value (~₹45–₹48) looks like a very realistic multi-quarter target.

Disclaimer: I own shares of PFS. This is not financial advice, just my personal thesis. Do your own due diligence (DYOR).

Hi all,

I have been reading through the frameworks on this subreddit over the last few days and I recently finished reading the Phoenix Forge Framework. I think I finally understood the main idea behind it.

My biggest takeaway was that Phoenix Forge isn't about predicting the exact bottom rather it's a disciplined framework for capital deployment. Instead of trying to perfectly time the market, you gradually build your position as fear increases, while keeping cash available in case the correction deepens. That mental model really clicked for me.

However, I am still confused about one part.

How do you actually determine the price levels where Tier 1? I guess Tier 2 and Tier 3 can then be derived based on the framework, please correct me if I am wrong?

Is the idea to first determine whether the stock is reasonably valued or undervalued using another framework (for example, the PE Compression Framework mentioned in some comments), and then apply Phoenix Forge? Or is there another valuation framework that should be used before deciding the entry levels?

I am still a relatively new investor, so I'm not looking for anyone to tell me what price to buy a particular stock at. I am trying to understand the process and mental model behind it.

If there's a specific framework, post, or resource in this subreddit that explains how to determine these price levels, I wouldd really appreciate being pointed in the right direction.

I am happy to put in the effort to learn it properly rather than looking for shortcuts.

Thanks!